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Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by various 
motor  and  non-motor  dysfunctions.  The  motor  symptoms  are  mainly  due  to  the  death  of  
dopaminergic (DAergic) neurons in the substantia nigra,  which  leads  to  loss  of  
neurotransmitter dopamine (DA) in the striatum and thus, to impairments in controlling 
movements. The causes behind PD are rather poorly understood but are likely to arise from 
genetic and environmental factors and their interactions. Current therapies for PD can only 
alleviate the symptoms, and there is a great need for interventions that could slow down the 
progression of the disease. Neurotrophic factors (NTFs) are polypeptides that regulate the 
development and survival of neurons, and therefore are promising molecules for the 
treatment of neurodegenerative disorders. Glial cell line –derived neurotrophic factor (GDNF) 
is  a  potent  NTF  for  DAergic  neurons,  and  the  discovery  of  novel  NTFs  could  stimulate  the  
development of regenerative therapies. A widely used tool in preclinical PD research to assess 
neurotrophic potential is the unilateral 6-hydroxydopamine (6-OHDA) –model in rodents. 
Furthermore, genetically modified mice can be useful in dissecting the mechanisms of 
neurodegeneration and identifying gene-environment –interactions. 
The  aims  of  this  thesis  were  to  study  the  neurotrophic  potential  of  a  structurally  modified  
GDNF –variant and vascular endothelial growth factor C (VEGF-C) in the unilateral 6-OHDA –
rat model of PD. Furthermore, the effects of 6-OHDA were assessed in two genetically 
modified mouse strains: one with a constitutively active GDNF -signalling receptor RET and 
the other expressing human A30P-mutated alpha-synuclein (aSyn). 
We  showed  that  the  removal  of  first  38  amino  acids  from  the  protein  sequence  of  GDNF  
increases its diffusion in the rat brain, but when compared with the full GDNF, is less effective 
in inducing behavioural recovery and protection of DAergic neurons. It is believed that GDNF 
is presented to its receptors by heparan sulphate proteoglycans of the extracellular matrix. The 
lack of heparin-binding domain may therefore lead to insufficient survival signalling.  
VEGF-C was identified as a neurotrophic factor for midbrain DAergic neurons. Pretreatment 
with VEGF-C before 6-OHDA –lesioning could effectively attenuate behavioural deficits in rats 
despite modest effects on DAergic neuronal survival. VEGF-C was not effective when given 
one month after 6-OHDA –lesioning. Furthermore, gliosis and disruption of the blood-brain 
barrier were observed after VEGF-C –injection. 
The studies on genetically modified mice showed that constitutive RET signalling can protect 
nigral DAergic neurons in MEN2B knock-in mice against 6-OHDA despite substantial 
depletion of striatal DA. The expression of A30P-aSyn did not sensitize the mice to the 
neurotoxic effects of 6-OHDA, but they exhibited an attenuated locomotor response to D-
amphetamine and developed notable motor defects with age. 
In conclusion, these studies provided new insights into the neuroprotective signalling of 
GDNF, lead to the identification of VEGF-C as a neurotrophic factor for DAergic neurons, and 
demonstrated that despite affecting the motor phenotype of mice, the expression A30P-aSyn 
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Parkinson’s disease (PD) is a progressive, neurodegenerative disease which is characterized by 
the loss of  dopaminergic (DAergic) neurons projecting from the substantia nigra (SN) to the 
striatum (Fahn, 2003). Deterioration of these neurons leads to the cardinal motor symptoms of 
PD: tremor at rest, rigidity, bradykinesia and postural instability. The motor symptoms begin 
to appear at a rather advanced stage of neurodegeneration but may be preceded by non-motor 
symptoms that also progress during the course of the disease. Non-motor symptoms include 
disorders of autonomic, sensory and neuropsychiatric functions. Another typical 
neuropathological hallmark of the disease, in addition to DAergic neurodegeneration, is the 
appearance of intracellular protein inclusions known as Lewy bodies. PD is usually diagnosed 
at  50-60  years  of  age,  and  it  affects  approximately  1%  of  the  population  over  70  years  
(Wirdefeldt et al., 2011). 
The triggering causes of the disease are still largely unknown, although an estimated 5-10% of 
cases have a known genetic background. Several genes associated with PD have been 
identified, but the large majority of PD cases are sporadic (Bekris et al., 2010). Evidently, 
oxidative stress, mitochondrial dysfunctions and inflammation play a role in the pathology of 
the disease (Fahn, 2003). The cornerstone of treating the motor symptoms of PD is levodopa 
(L-DOPA), which is metabolized to dopamine (DA) in the remaining DAergic neurons in the 
brain. However, as the disease progresses, L-DOPA becomes less effective and causes motor 
complications such as wearing-off and dyskinesia. There is a great need for therapeutical 
interventions that could slow down the progression of the disease. 
Neurotrophic factors (NTFs) are polypeptides that participate in the development and survival 
of neurons. Current classification recognizes three groups or families of NTFs: neurotrophins, 
glial cell line –derived neurotrophic factor (GDNF) family of ligands (GFLs), and neurokines 
(Bespalov and Saarma, 2007). Additionally, there are various other growth factors that serve 
their  main  function  outside  the  nervous  system,  but  also  affect  neurons.  Because  of  their  
ability to support neurons, NTFs are studied as possible future therapeutics for various 
neurodegenerative disorders, including PD. One of the most widely used methods to model 
PD in experimental animals is to inject a catecholaminergic neurotoxin 6-hydroxydopamine 
(6-OHDA) unilaterally into the nigrostriatal pathway in rodents (Blum et al., 2001). 6-OHDA-
induced neuronal death occurs mainly because of oxidative stress and mitochondrial 
dysfunction, both of which are also implicated in PD. A long list of NTFs have shown potential 
in protecting DAergic neurons from neurodegeneration and improving behavioural deficits in 
6-OHDA-treated rodents, but so far these findings have not translated to the clinical level. 
GDNF and neurturin  (NRTN)  are  so  far  the  only  NTFs  that  have  been  given  to  PD patients.  
Because of controversial outcomes, trials with GDNF have been discontinued, while NRTN 
trials are still ongoing. Despite yet inconclusive evidence of their clinical applicability, NTFs 
(or small molecules with similar effects), could provide a unique way of repairing the damaged 
the brain and protecting the remaining DAergic neurons.  




2. Review of the literature 
 
2.1 Parkinson’s disease 
PD is a progressive neurodegenerative disorder, which was first defined in detail by James 
Parkinson in An Essay on the Shaking Palsy in 1817. He describes cases that suffer from 
involuntary trembling of limbs, rigidity of muscles, as well as difficulties in executing 
movements and holding an upright posture.  A number of  other symptoms are listed as well,  
and it is recognized that the physical state, but not the senses or the intellect, of the patients 
deteriorates slowly but relentlessly in the course of time. The neuropathology and the 
proximate cause of the disease remained unsolved, and even today many questions concerning 
those aspects of the disease are still unanswered.  
The prevalence of PD is approximately 1000/100,000 in population over 70 years of age, which 
makes it the second most common neurodegenerative disorder after Alzheimer’s disease (AD), 
and the most common neurodegenerative movement disorder  (Wirdefeldt et al., 2011). Since 
the prevalence increases with age, the number of cases is expected to rise notably in the 
ageing population during the coming decades (Hirtz et al., 2007). This, in turn, will add to the 
burden of medical costs. 
The  etiology  of  PD  is  complex,  and  is  likely  to  arise  both  from  genetic  and  environmental  
factors, as well as their interactions. There are altogether 18 genes/loci that are indicated in 
monogenic forms or as susceptibility factors for the disease,  but so far only six of  them have 
been  well  validated  as  causes  of  monogenic  familial  PD,  accounting  for  5-10%  of  cases  
(Table 1., Bekris et al., 2010). Common polymorphisms in the SNCA and LRRK2 –genes have 
been identified as susceptibility factors as well. There is suggestive evidence that exposure to 
pesticides may increase the risk to develop PD, whereas coffee and smoking seem to be 
protective. All in all, there is very little conclusive data about various life-style or 
environment -related factors and their causal relationships with PD, which may partly be due 
to high variation in experimental setups (Wirdefeldt et al., 2011).  
The clinical manifestation of PD is characterized by typical motor symptoms of parkinsonism 
(a  neurological  syndrome  whose  primary  cause  is  PD,  but  can  be  related  to  other  
neurodegenerative disorders or caused by secondary environmental factors), which include 
bradykinesia, tremor at rest, rigidity, loss of postural reflexes, flexed posture and the freezing 
phenomenon.  At  least  two  of  these  symptoms  need  to  be  present  when  diagnosis  of  
parkinsonism is done, one of them being either of the two first mentioned in the list (Hughes 
et al., 1992). In PD, the symptoms typically start asymmetrically and are significantly alleviated 
by L-DOPA -therapy (Fahn, 2003). In addition to the motor deficits, PD is accompanied by 
non-motor symptoms. These include various cognitive, neuropsychiatric, autonomic, sensory 
and sleep disturbances, which represent the outcome of neurodegeneration in other 
neurotransmitter systems than DAergic –namely serotonergic, noradrenergic or cholinergic. 
Many of the non-motor symptoms are already present before the motor defects appear (Park 
and Stacy, 2009).  




Table 1. Well-validated genes associated with PD (modified from Bekris et al. 2010) 
PARK locus Gene ADo/AR Type of mutation 
PARK1/PARK4 SNCA 
(alpha-synuclein) 
ADo missense mutations (A30P, A53T, 
E46K), duplication/triplication of gene 
PARK2 Parkin 
(ubiquitin ligase) 
AR exonic deletions, missense and 
nonsense mutations, duplication 
PARK6 PINK 1 
(kinase) 




AR missense mutations 
PARK8 LRRK2 
(tyrosine kinase –like protein) 
ADo missense and nonsense mutations 
PARK9 ATP13A2 
(membrane ATPase) 
AR missense mutations 
ADo=autosomal dominant, AR=autosomal recessive 
 
The neuropathological hallmark of PD is the degeneration of DAergic neurons in the 
substantia nigra pars compacta (SNpc),  which  subsequently  leads  to  the  loss  of  DA  in  the  
striatum. The loss of DA can be substantially compensated, since the motor symptoms start to 
appear only when about 80 % of striatal DA is lost, and 30-60 % of nigral DAergic neurons and 
50-60 % of their striatal terminals have degenerated (Fahn, 2003, Cheng et al., 2010). However, 
neurodegeneration in the brain is not limited to the nigrostriatal DAergic system, but also 
affects other neurons (Jellinger, 1991). In addition, nigral cell loss is accompanied by gliosis, 
microgliosis and inflammation. Another typical neuropathological feature of PD is the 
appearance of dense intracellular aggregates called Lewy bodies (LB), in which -synuclein 
(aSyn) is a major component. LBs are not only found in surviving nigral DAergic neurons, but 
the widespread pathology can be observed throughout the central, peripheral and enteric 
nervous system (Jellinger, 2012). aSyn is a presynaptically concentrated, predominantly 
unfolded protein that is prone to conformational changes (reviewed by Surguchov, 2008). Its 
main roles in the central nervous system are in maintenance of vesicle pools, transmitter 
release, lipid metabolism, regulation of proteasomal function and even neuroprotection. How 
aSyn becomes pathogenic still remains unsolved and is under vigorous studies. The prevailing 
concept is that the most toxic forms of aSyn are protofibrils and oligomers, formation of which 
may be induced by several factors, e.g. changes in the physicochemical environment or 
accumulation  of  the  protein,  mutations,  and  oxidative  stress.  Toxic  aSyn-species  can  form  
pore-like structures on cell membranes, disrupt axonal transport and interfere with protein 
turnover. It is likely that Lewy bodies are an outcome of neuronal protection machinery that 
deposits harmful proteins into aggregates. 
Medical  treatment  of  the  cardinal  symptoms  of  PD  is  largely  based  on  DA  replacement  
therapy by L-DOPA, which is converted into DA by aromatic L-amino acid decarboxylase 
(AADC) (Fig.1). L-DOPA is always combined with AADC inhibitors (benserazide, carbidopa) 
and often with catechol-O-methyltransferase inhibitors (entacapone, tolcapone) to prevent L-




DOPA being metabolized into DA in the periphery before reaching its target in the brain. L-
DOPA is the most effective therapy, but its efficacy is reduced as the disease progresses, which 
leads  to  motor  complications  such  as  involuntary  movements  and  fluctuations  in  motor  
performance. Other drugs used are monoamine oxidase (MAO)-B –inhibitors (selegiline, 
rasagiline) that prevent DA metabolism in the brain, DA agonists (e.g. bromocriptine, 
pramipexole, ropinirole, rotigotine), and more seldomly anticholinergic drugs (e.g. biperiden) 
or amantadine. The available medicines alleviate the motor symptoms of the disease, but none 
of them can halt the progressive neurodegeneration.  
 
 
Figure 1. Synthesis and metabolism of dopamine (DA). Amino acid L-tyrosine is converted by 
the rate-limiting enzyme tyrosine hydroxylase (TH) into L-DOPA, which in turn is converted to DA 
by aromatic L-amino acid decarboxylase (AADC). Newly synthesized DA is packed into vesicles via 
the vesicular monoamine transporter 2. Once released into the synaptic cleft, DA is rapidly reuptaken 
to the neuron via the dopamine transporter (DAT) and restored into vesicles, or partly metabolized 
by the mitochondrial enzyme monoamine oxidase (MAO). DA is also partly transported into post-
synaptic  neurons  or  glial  cells  via  uptake  2  (U2),  and  metabolized  by  MAO  and  catechol-O-
methyltransferase (COMT). 
 
2.2 6-hydroxydopamine –based rodent models of PD 
Various approaches have been used in attempt to model PD in experimental animals (Kirik et 
al., 2002, Bezard and Przedborski, 2011, Blesa et al., 2012). These include (but are not limited 
to) 1) the use of neurotoxins such as 6-OHDA, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), metamphetamine, rotenone and paraquat, 2) induction of parkinsonian state with 
reserpine, which depletes nerve endings of DA, 3) induction of neurodegeneration through 
sustained neuroinflammation caused by lipopolysaccharide, 4) creation of genetically 
engineered mice carrying PD –related mutated genes and 5) overexperssion of aSyn in the 
nigrostriatal pathway via viral transfection. None of the current models can fully reproduce 
the range of neuropathological and behavioural defects seen in PD (see paragraph 2.1), and 
many of them are mainly focused only on DAergic neurodegeneration. Additionally, although 
they have been very useful in predicting the efficacy of symptomatic treatment, the translation 




of effective neuroprotection into humans has been less successful. Nevertheless, all of these 
tools have provided us with important information regarding the molecular mechanisms and 
regulation of DAergic cell death. 
There are extensive reviews covering various aspects, including molecular mechanisms of 
neurodegeneration and behavioural and neurobiological changes, of the 6-OHDA –rodent 
models  of  PD  (Schwarting  and  Huston,  1996a,  Schwarting  and  Huston,  1996b,  Blum  et  al.,  
2001, Deumens et al., 2002). 6-OHDA, a hydroxylated analogue of DA, occurs naturally in very 
small amounts in rodent and human brain. It does not cross the blood-brain barrier (BBB), 
and therefore has to be injected straight into the brain in a stereotaxic operation to create a 
DAergic lesion. 6-OHDA is taken into catecholaminergic neurons via the DA transporter 
(DAT) and the noradrenaline transporter, although it has been shown that unspecific damage 
to other neurons can also occur especially with high concentrations of 6-OHDA. Although the 
toxic mechanisms of 6-OHDA are not fully understood, it is known that neural damage caused 
by the toxin is mainly due to two reasons. Firstly, rapid auto-oxidation and, to a lesser extent, 
deamination of the toxin by MAO-B generates reactive oxygen species such as hydrogen 
peroxide, hydroxyl and superoxide radicals and quinones. Their formation is likely to be 
enhanced by iron. Secondly, 6-OHDA can inhibit mitochondrial complex 1, which is a part of 
the oxidative phosphorylation system that produces adenosine triphosphate. These processes 
lead to DAergic neuronal death, which seems to happen both via apoptosis (programmed cell 
death) and necrosis. Importantly, both oxidative stress and mitochondrial dysfunction are 
implicated in PD.  
6-OHDA is traditionally administered unilaterally (because of severe disability related with 
extensive bilateral lesions) into one of three locations: to the striatal terminal area, to the 
medial forebrain bundle (MFB) that contains the nigrostriatal (as well as mesolimbic) DAergic 
axons, or to the SN containing the DAergic cell somas (Deumens et al., 2002). The two latter 
ones represent a rapidly developing, acute lesion, which leads to extensive loss of DAergic 
neurons. The lesion is fully developed already in 3-5 days, assessed as decreased DA content in 
the  striatum.  Administration  of  6-OHDA  into  the  MFB  usually  results  in  a  total  lesion,  in  
which at least 90 % of striatal DA and nigral tyrosine hydroxylase (TH)-positive neurons are 
lost. The extent of the lesion is better controlled and varied with intranigral administration, 
depending on the injection site and dose of the toxin. Therefore, it is possible to create partial 
lesions with intranigral 6-OHDA –injections. Striatal lesions are virtually always partial 
lesions, although again by careful choice of dose and site of 6-OHDA it is possible to create 
lesions of varying severity (Kirik et al., 1998). The most important difference between striatal 
lesions  and  those  created  closer  to  nigral  cell  somas  is  that  striatal  lesions  cause  a  much  
slower, retrograde neurodegeneration that develops during several weeks. Neuronal death at 
the level  of  the SN is  first  observed about one week post lesioning,  and is  most rapid until  2  
weeks post-lesion followed by a slower but progressive neurodegeneration up to at least 8 
weeks post-lesion (Sauer and Oertel, 1994).  
To assess the severity of the unilateral lesion, and the efficacy of potential therapeutic 
molecules in alleviating 6-OHDA –induced behavioural impairments, several behavioural tests 
can  be  employed  (Deumens  et  al.,  2002).  One  of  the  best  known  methods,  drug-induced  




rotational behaviour, was described by Ungerstedt and Arbuthnott (1970). In this test, the 
animal receives an injection of amphetamine to release DA or apomorphine to activate 
postsynaptic DA receptors. Due to imbalance of DAergic transmission between the brain 
hemispheres, this will cause the animal to exhibit rotational movement. Administration of 
amphetamine makes the animal turn ipsilaterally,  i.e.  towards the side of  the lesion,  because 
of greater DA release in the intact striatum. Apomorphine causes contralateral turning due to 
dominant activation of sensitized DA receptors in the lesioned striatum. Apomorphine can be 
reliably used only in animals with extensive striatal DA loss, because compensatory 
sensitization of the postsynaptic receptors is not seen with mild lesions. Generally, the bigger 
the imbalance in DAergic activity between the brain hemispheres after the 6-OHDA-
treatment (i.e. the larger the lesion), the more the animals rotate. Especially the loss of TH-
cells in the medial SN is associated with enhanced rotational behaviour (Olds et al., 2006). 
It  is  also  possible  to  measure  locomotor  activity  without  any  drug  administration,  since  
6-OHDA can cause a reduction in normal activity of the animals. Other commonly used tests 
that do not require a drug challenge are cylinder test, forelimb akinesia test and staircase test 
(Montoya et al., 1991, Olsson et al., 1995, Schallert et al., 2000). In the cylinder test, the animal 
is  placed  into  a  transparent  plexiglass  cylinder,  and  during  the  test  period  (usually  5  min)  is  
scored for simultaneous and asymmetric front paw contacts with the cylinder. The forelimb 
akinesia test for rats measures the ability to initiate and execute movements. The rat is 
immobilized  by  the  experimenter  so,  that  only  one  front  paw  can  be  used  and  placed  on  a  
table surface. The rat is then moved in forehand direction and backhand direction along the 
table edge, and the number of adjusting paw steps, as well as the latency to initiate the steps, 
are measured. Staircase test measures skilled paw use and fine motorics of rats. In this test, 
rats are placed in an apparatus consisting of a starting chamber with an opening to a platform. 
After entering the platform, the rat will start picking up glucose pellets from descending stairs 
that are placed on both sides of the platform. Number of pellets retrieved and the lowest level 
of stairs reached are scored. In all of these tests without drug challenge, impairment in the use 
of front paw contralateral to the lesioned hemisphere is usually seen. 
Despite being a valuable tool in PD research, the 6-OHDA-model has its limitations 
(Deumens et al., 2002). First, a unilateral model does not fully represent the bilateral clinical 
disease, but the use of a bilateral 6-OHDA-model brings about animal welfare problems 
(adipsia  and  aphagia  are  common).  Second,  most  of  the  behavioural  tests  are  developed  to  
measure  motor  asymmetry.  In  addition,  the  brain  can  compensate  for  the  loss  of  DAergic  
neurons. For example, with time the remaining TH-positive fibers in the lesioned striatum can 
undergo sprouting, which can lead to at least partial spontaneous recovery (Blanchard et al., 
1996). This sprouting can even emerge from the non-lesioned side. Finally, variation is rather 
high in the 6-OHDA-model, not only between experimental subjects but also within one 
subject in the case of a bilateral lesion, and in the correlation between behavioural and 
morphological measures. Also, small lesions are difficult to quantify in terms of behavioural 
changes. Naturally, all the other models of PD have their limitations as well, and therefore it is 
more important to know which aspects of the disease are represented by each of them. 




2.3 Potential therapeutic neurotrophic factors identified in the 6-OHDA –
model of PD 
Neurotrophic factors (NTFs) are proteins that participate in the regulation of various 
processes during the lifespan of a neuron. They regulate the proliferation of neuronal 
precursors and their differentiation, morphological maturation and neurite outgrowth as well 
as synaptogenesis and synaptic plasticity. According to a classical theory based on the early 
studies by Rita Levi-Montalcini and her co-workers starting in the 1940’s, NTFs are secreted by 
a target tissue in very small  amounts,  which attracts neuronal processes to form connections 
with the target. Because of limited amounts of NTFs available, only the neurons that are able 
to form meaningful connections with the target stay nourished with the NTFs while those that 
failed  to  properly  innervate  the  tissue  die  apoptotically.  It  is  believed  that  NTFs  can  act  in  
autocrine manner as well. NTFs are currently classified into three families: neurotrophins, 
GFLs, and neurokines (Bespalov and Saarma, 2007). The neurokines, or neuropoietic cytokines 
are a group of small proteins (interleukins 6, 11, 27, leukaemia inhibitory factor, ciliary 
neurotrophic factor, cardiotrophin 1, neuropoietin, cardiotrophin-like cytokine and B-cell 
stimulating  factor  3)  that  have  well-known  functions  outside  the  nervous  system,  but  also  
have  roles  in  the  developing  and  adult  brain  and  in  brain  injuries  (Bauer  et  al.,  2007).  
Additionally, there are many growth factors that are better known for their effects on tissues 
outside  the  nervous  system,  but  can  also  act  as  neurotrophic  factors.  These  include  for  
example the vascular endothelial growth factor (VEGF) family proteins, erythropoietin (EPO) 
and  insulin-like  growth  factor  1  (IGF1).  The  following  paragraphs  will  focus  on  describing  
neurotrophins, GFLs, VEGF-ligands and some other selected proteins identified as NTFs for 




Overview of neurotrophins and their signalling 
Neurotrophins  are  the  first  family  of  NTFs  described,  and  it  includes  nerve  growth  factor  
(NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 
(NT-4, in literature also referred to neurotrophin-5 or neurotrophin-4/5) (Huang and 
Reichardt, 2001, Skaper, 2008). Additional neurotrophins (6 and 7) have been identified in 
Xenopus and fish.  In general,  these proteins are active as homodimers,  but the subunits may 
form heterodimers as well. They are all synthesized as proproteins, which are secreted and 
then cleaved by proteases to yield mature neurotrophins. The pro-neurotrophins are active 
molecules as well, but they have dramatically different actions from those of mature forms. 
Neurotrophins signal through three transmembrane receptor tyrosine kinases: TrkA, TrkB and 
TrkC, which dimerize when they bind neurotrophins (Fig. 2.). The fourth receptor, p75NTR is 
structurally unrelated to Trk-receptors, and is rather a distant member of the tumour necrosis 
factor receptor family. It lacks a catalytic domain, but contains a particular death domain in its 
cytoplasmic part and acts through protein-protein interactions. Sortilin has also been 
recognized as an important receptor for neurotrophins (Nykjaer et al., 2004). Signalling of 




these receptors can be modulated on many levels, and this complexity lies behind the plethora 
of effects that NTFs can have on various neurons and cells (Huang and Reichardt, 2001, Teng 
and Hempstead, 2004). An interesting feature of neurotrophins is that, while mature proteins 
activate Trk-receptors, p75NTR and  their  combinations  to  induce  either  cell  survival  or  
apoptosis, pro-neurotrophins selectively activate p75NTR in collaboration with sortilin to 
induce apoptosis (Lee et al., 2001, Nykjaer et al., 2004, Teng et al., 2005).  
Signalling pathways that are activated by neurotrophins have been reviewed in detail, for 
example  by  Huang  et  al  (2001).  In  summary,  the  activation  of  Trk  receptors  leads  to  
phosphorylation of tyrosine residues in the cytoplasmic domains. A number of adaptor 
proteins connect Trk activation with intracellular signalling cascades, including MEK/MAPK 
(MAP-kinase-kinase/mitogen-activated protein kinase) mediating differentiation and survival 
of neurons, PI3K/Akt (phosphatidylinositol3´ -kinase/ Akt kinase) implicated in neuronal 
survival, and PLC  (phospholipase gamma) mediating neurite outgrowth. Signalling through 
p75NTR activates nuclear factor – B  to  induce  neuronal  survival,  or  Jun-kinase  and  acidic  
sphingomyelinase (latter leading to formation of ceramide) to cause apoptosis. p75NTR 
activation can also lead to modifications in cytoskeleton dynamics controlling neurite 
outgrowth. 
 
Neuronal effects of neurotrophins 
A variety of neurons and neuronal processes in the peripheral as well as in the central nervous 
system are responsive to neurotrophin signalling, as has been demonstrated in numerous 
cultured cell systems and animal models. Neuronal populations, whose survival depend at 
least partially on neurotrophin-Trk -activity include the sensory neurons of trigeminal ganglia, 
dorsal root ganglia (DRG), trigeminal mesencephalic nucleus, vestibular and cochlear ganglia, 
sympathetic ganglia, motor neurons, enteric neurons, cerebellar granule cells, retinal ganglion 
cells, cholinergic neurons and DAergic neurons (Hyman et al., 1991, Ruit et al., 1992, Yan et al., 
1992, Avila et al., 1993, Ibanez et al., 1993, Lindholm et al., 1993, Morse et al., 1993, von Bartheld 
and Bothwell, 1993, Yan et al., 1993, Cohen et al., 1994, Cohen-Cory and Fraser, 1994, Ernfors et 
al.,  1995,  Huang  et  al.,  1999,  Chalazonitis  et  al.,  2001).  In  addition,  survival,  proliferation  or  
differentiation (Ghosh and Greenberg, 1995, Vicario-Abejon et al., 1995) is induced in 
precursors of oligodendrocytes, cortical and hippocampal neurons and in cultured neural crest 
cells (Kalcheim et al., 1992, Barres et al., 1994, Scarisbrick et al., 2000).  
BDNF and NT-4 also have a specific and important function in guiding the formation of ocular 
dominance columns (ODCs) through TrkB. The formation of ODCs is inhibited when these 
molecules  are  scavenged  by  an  immunoglobulin-bound  TrkB  (Cabelli  et  al.,  1997).  On  the  
other  hand,  if  BDNF  or  NT4  is  applied  in  supraphysiological  concentrations  onto  the  
developing visual cortex, the ODCs fail to form as well, which suggests that correct amounts of 
neurotrophins are critical for the process (Cabelli et al., 1995). 
An important phenomenon regulated by neurotrophins is long term potentiation (LTP) to 
strengthen synaptic function, and synaptic plasticity (Lohof et al., 1993, Kang and Schuman, 
1995). LTP is severely reduced in the hippocampi of BDNF and NT-4 knock-out mice, as well 
as in normal hippocampal slices treated with a BDNF/NT-4 scavenging decoy TrkB (Korte et 




al., 1996, Chen et al., 1999, Xie et al., 2000). Of note is the role of BDNF and TrkB signalling in 
the effects of antidepressants. Treatment with antidepressants can upregulate the expression 
of  BDNF  and  TrkB  mRNA  in vivo,  and  TrkB  can  be  activated  by  the  treatment  even  in  the  
abscence of BDNF (Nibuya et al., 1995, Saarelainen et al., 2003, Rantamäki et al., 2011). Studies 
in TrkB –deficient mice have shown, that the receptor and its activation are required for 
antidepressant –induced behavioural changes (Saarelainen et al., 2003). It has been suggested 
that during antidepressant treatment, a developmental state –like plasticity is driven by 
activity-dependent expression of BDNF and that it is a pivotal element in the process that 
leads to optimal rewiring of neuronal networks by environmental guidance (such as 
psychotherapy) (Castren and Rantamäki, 2010). 
 
 
Figure 2. Neurotrophins, their receptors and effects on neurons. Neurotrophins act as dimers 
to activate the receptors, which also dimerize upon ligand binding. On Trk –receptors the 
intracellular tyrosine kinase domains are transphosphorylated. p75NTR does not contain a kinase 
domain. The three Trk-receptors respond to specific neurotrophins (marked in black), whereas NT-3 
is able to activate all of the receptors at least to some extent. p75NTR is activated by all members of the 
neurotrophin family, as well as pro-neurotrophins, and it can interact with each of the Trk-receptors. 
Figure adapted from Chao, 2003 and Teng and Hempstead, 2004. 




Roles of neurotrophins in the intact nigrostriatal DAergic system and associations 
with PD 
Among  the  neurotrophin  family  members,  BDNF,  NT-3  and  NT-4  seem  to  be  strongly  
associated with DArgic function and the nigrostriatal pathway. mRNAs of BDNF and NT-4 as 
well as their receptors TrkB and TrkC are expressed on DAergic neurons (Seroogy and Gall, 
1993,  Seroogy  et  al.,  1994,  Numan  and  Seroogy,  1999).  At  least  BDNF  is  retrogradely  
transported to the SN after intrastriatal infusions (Mufson et al., 1994). Although TrkA is 
normally not expressed on DAergic neurons, induction of TrkA via adeno-associated viral 
(AAV) vector in the rat brain leads to expression of the receptor as well as retrograde transport 
of exogenously applied NGF (Melchior et al., 2003).  
Despite being expressed and having positive effects on DAergic neurons, neurotrophins do not 
seem to be crucially required for normal development of midbrain DAergic pathways (Ernfors 
et al., 1994, Klein, 1994, Liu et al., 1995). On the other hand, the role of a specific NTF in the 
development and maintenance of neurons may not be simple to assess in traditional knock-
out animals, because compensatory mechanisms may obscure a relevant phenotype. In 
support  of  this,  an  injection  of  BDNF  –neutralizing  antibodies  into  the  developing  SN  of  
normal  mice  leads  to  increased  natural  postnatal  apoptosis  of  DAergic  neurons  (Oo  et  al.,  
2009).  Loss  of  nigral  TH-positive  neurons  is  also  observed  in  adult  rats  after  an  infusion  of  
antisense oligonucleotides inhibiting the expression of BDNF (Porritt et al., 2005). 
Additionally, reduced expression levels of TrkB and C –receptors also lead to degeneration and 
morphological defects in nigrostriatal neurons (Zaman et al., 2004, von Bohlen und Halbach et 
al., 2005). 
Under in vitro -conditions, BDNF, NT-3 and NT-4 increase the survival of mesencephalic 
DAergic neurons, whereas NGF is without effect (Hyman et al., 1994, Hynes et al., 1994, 
Spenger et al., 1995). When administered into intact rat brain, neurotrophins can boost the 
DAergic system. Even a single intranigral injection of BDNF can cause contralateral rotational 
behaviour in rats after administration of amphetamine, although the striatal DA 
concentrations are slightly decreased (Shults et al., 1994). Two-week intranigral and 
intrastriatal infusions of BDNF increases striatal DA turnover, and contralateral rotational 
behaviour is induced by amphetamine in rats (Altar et al., 1992). Similar augmentation was 
later seen with NT-3 and NT-4 (Altar et al., 1994a, Martin-Iverson et al., 1994). Furthermore, a 
BDNF-infusion into the SN increases the number of spontaneously active DAergic neurons, 
and elevates their firing rate (Shen et al., 1994). 
Although  it  is  not  clear  if  neurotrophins  play  a  role  in  the  pathogenesis  or  compensatory  
changes in PD, alterations in serum levels and brain expression of neurotrophins have been 
detected in PD patients. Scalzo et al. (2010) reported that serum BDNF –levels are reduced in 
PD  patients,  most  notably  in  the  early  stages  of  the  disease.  Thus,  higher  concentrations  of  
BDNF were detected in patients with longer disease duration and more severe motor 
impairments. Similar changes in plasma levels and associations with disease severity were 
observed with NGF (Lorigados Pedre et al., 2002). It has also been demonstrated that amounts 
of BDNF protein and mRNA are reduced in the SN, caudate and putamen in PD (Mogi et al., 
1999, Parain et al., 1999, Howells et al., 2000). Most of the DAergic neurons in the SN normally 




express  BDNF,  which  means  that  the  nigral  loss  of  BDNF partially  results  from the  death  of  
DAergic neurons. However, Howells et al. (2000) found reduced BDNF expression in the 
surviving DAergic cells in PD. TrkB-levels in the surviving neurons remain normal (Benisty et 
al., 1998). In contrast to all these reports describing lower levels of BDNF in PD brains, Salehi 
et  al.  (2009)  found  robustly  elevated  concentrations  of  BDNF  in  the  cerebrospinal  fluid  of  
patients. They proposed that the source of excess BDNF is activated glia.  
 
Effects of neurotrophins in the 6-OHDA –model of Parkinson’s disease 
The potential of neurotrophins (mainly BDNF) as dopaminotrophic factors has been explored 
in numerous studies.  In addition, these studies have revealed that 6-OHDA -lesioning can 
increase the nigrostriatal expression of TrkB mRNA and slightly decrease TrkC –levels, 
whereas BDNF protein levels can either rise or decline in young and old rats, respectively 
(Zhou et al., 1996, Numan and Seroogy, 1999, Yurek and Fletcher-Turner, 2000, Yurek and 
Seroogy, 2000, Yurek and Fletcher-Turner, 2001). In one study, no changes were detected in 
nigral BDNF levels after 6-OHDA (Mocchetti et al., 2007). 
BDNF 
Spina et al. (1992) were the first ones to report the neuroprotective activity of BDNF against 6-
OHDA in cultured rat mesencephalic DAergic neurons. In in vivo -setups, BDNF has been 
delivered as multiple doses or continuously via various applications such as secreting cells or 
viral transfection, results of which are summarized in Table 2. There are also experimental 
therapies that have beneficial effects in the 6-OHDA rat model and may partially act via 
upregulation of BDNF expression. These therapeutic candidates include a gamma-
aminobutyric acid (GABA) receptor B -antagonist CGP 56999A and Leu-Ile –dipeptide (Nitta 
et al., 2004, Enna et al., 2006) 
The outcomes of neuroprotection studies where recombinant BDNF was used are partially 
conflicting (Altar et al., 1994b, Shults et al., 1995), which may be explained by the differences 
in  administration  of  both  the  NTF and 6-OHDA.  BDNF -gene  transfer  either  into  the  SN or  
STR significantly inhibits the development of rotational bias when 6-OHDA is administered 
weeks or months later, but these treatments have failed to protect TH-positive cells from 
degeneration (Klein et al., 1999). Another approach for long-term administration of BDNF, 
intrastriatally implanted BDNF-secreting rat primary fibroblasts, could almost completely 
prevent the loss of DAergic nerve terminals when a partial 6-OHDA –lesion was induced two 
weeks later (Levivier et al., 1995). It should be noted though, that more extensive lesions were 
employed in the studies utilizing viral transfection than in the study with secreting fibroblasts.  
Neurorestoration experiments with BDNF are few. In two of them, BDNF-secreting 
transfected astrocytes were used, and a reduction in rotational behaviour was observed 
without significant protection of nigral TH-positive neurons (Yoshimoto et al., 1995).  Also 
implanted BDNF-expressing and secreting human mesenchymal stem cells can prevent the 
augmentation of metamphetamine-induced rotational behaviour in rats with nigral 6-OHDA –
lesions (Somoza et al., 2010). In contrast to the studies with transfected astrocytes, higher TH-
immunoreactivity was seen in the striatum, accompanied by slightly enlarged TH-cell bodies 




in the SN in BDNF-cell treated rats. This discrepancy may be due to a shorter interval between 
lesioning and treatment. 
Collectively,  there  are  several  reports  describing  the  functional  efficacy  of  BDNF  in  the  
6-OHDA rat model of PD. Although some groups have found increased survival or sprouting 
of DAergic neurons, surprisingly many papers describe a rather robust functional recovery 
without measurable neuroprotection. This is especially seen in neurorestoration experiments, 
none of which shows significant preservation of nigral DAergic cells. Thus, the recovery of 
motor functions may arise for example from enhanced functionality of surviving DAergic 
neurons, or some compensatory events in other neurotransmitter systems. 
 
Table 2. Neuroprotective and neurorestorative effects of BDNF in the 6-OHDA –rat model 
of PD. Table includes summaries of behavioural changes, protection of striatal DA and nigral or 
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15 days after 1x3.5 µg, SN AMPH  
 
n.m. STR 0 
SN 0 
 






2x4µg, SN APO  
 
n.m. SN 0 TUNEL+ 
cells, SN  
(Somoza et 
al., 2010) 
hMSC, 2xSN 1 w after 3x1.33µg, SN AMPH  
 
n.m. STR  TH-cell 
size  
AAV= adeno-associated virus, AMPH= amphetamine-induced rotational behaviour, APO= 
apomorphine –induced rotational behaviour, DAT=dopamine transporter, hMSC= human mesenchymal 
stem  cells,  HSV1=  herpes  simplex  virus  1,  SN=substantia  nigra,  STR=striatum.  Responses  of  BDNF-
treated animals vs. lesion control animals: 0=no change, = increased, =decreased n.m.= not 
measured. 
 
NT-3, NT-4 and NGF 
Although NT-3 and NT-4 clearly affect DAergic neurons positively, their neuroprotective and 
neurorestorative potential has not been sufficiently studied in the 6-OHDA rat model of PD. 
In fact,  the only report is  by Altar et  al.  (1994b) who studied NT-3 in the same protocol  they 




used with BDNF (see Table 2). NT-3 was infused for two weeks intranigrally beginning six days 
before and then continuing for eight more days simultaneously with an intrastriatal 6-OHDA 
infusion. The behavioural effects were similar but less robust than with BDNF. Striatal DA 
levels or metabolism, however, were not affected. 
Not  surprisingly,  reports  concerning  effects  of  NGF  in  6-OHDA  –models  are  few  and  
inconclusive, since it generally does not have dopaminotrophic activity. However, Chaturvedi 
et al. (2006) have reported that amphetamine-induced ipsilateral rotations are fewer and 
striatal  as well  as nigral  DA concentrations are higher in intranigrally lesioned rats that have 
received NGF into striatum three weeks post lesioning. They also found an increase in the 
survival  of  TH-positive  neurons  in  the  SN.  In  an  earlier  study,  a  six-week  
intracerebroventricular delivery of NGF was without effect in rats with nigral lesions, when 
the treatment was started four weeks after 6-OHDA delivery (Bergdall and Becker, 1994). 
 
2.3.2 GDNF-family of ligands 
Overview of GFLs and their signalling 
Four proteins comprise the GFLs: GDNF, NRTN, artemin (ARTN) and persephin (PSPN). 
GDNF was  the  first  member  to  be  found in  rat  B49  glial  cell  line,  and  was  reported  to  have  
potent neurotrophic effects on DAergic neurons (Lin et al., 1993). NRTN was found some years 
later as a trophic factor for sympathetic and sensory neurons (Kotzbauer et al., 1996). The last 
two members, PSPN and ARTN, were identified with homology cloning and database search 
(Baloh et al., 1998, Milbrandt et al., 1998). The GFLs are distant members of the transforming 
growth factor-  (TGF- ) superfamily, based on conserved locations of seven cystein recidues 
in the amino acid sequence. The proteins are expressed as precursors, preproproteins, which 
are proteolytically cleaved to mature proteins that form homodimers (Airaksinen and Saarma, 
2002). At least GDNF is expressed in two alternatively spliced variants, in which the pro-
sequences differ (Lonka-Nevalaita et al., 2010).  
The GFLs use a complicated multicomponent signalling receptor system. It was first shown 
that the transmembrane receptor tyrosine kinase RET (rearranged during transfection) is a 
main signal transducer for GDNF, and that the presence of a cell-surface glycosyl 
phosphatidylinositol (GPI) –linked co-receptor is required for RET activation (Jing et al., 1996, 
Treanor et al., 1996, Trupp et al., 1996). Now there are altogether four GPI –linked co-receptors 
known to interact with RET: GDNF-family receptors (GFR) 1-4, which all preferentially bind 
only  one  of  the  family  ligands  (Fig.3)  (Baloh  et  al.,  1997,  Jing  et  al.,  1997,  Baloh  et  al.,  1998,  
Thompson et al., 1998, Worby et al., 1998, Masure et al., 2000, Scott and Ibanez, 2001, Sidorova 
et  al.,  2010).  It  is  not fully understood, how and in which order the interactions between the 
ligands, RET and co-receptors are established, but in general the active signalling complex is a 
heterotetramer  consisting  of  two  units  of  RET  and  two  units  of  co-receptors  (Bespalov  and  
Saarma, 2007). GFR 1, GFR 2 and GFR 4 exist in alternatively spliced isoforms, which may 
induce disparate signalling pathways and have distinct roles during development (Baloh et al., 
1997,  Lindahl et  al.,  2000,  Dolatshad et  al.,  2002,  Yoong et  al.,  2009).  Soluble forms of  GFR 1 
and GFR 4 are found as well, and they can trigger signalling different from the membrane-
bound form, or even independent of  ligand binding (Paratcha et  al.,  2001,  Mikaels-Edman et 




al.,  2003,  Yang  et  al.,  2007).  Also  RET is  expressed  in  two isoforms,  RET9 and RET51,  which  
differ  in  their  intracellular  domains  (Tahira  et  al.,  1990).  They  do  not  interact  with  or  fully  
compensate for each other, and they have distinct tissue distributions (Tahira et al., 1990, de 
Graaff et al., 2001, Tsui-Pierchala et al., 2002a, Tsui-Pierchala et al., 2002b, Yoong et al., 2005). 
To add more complexity to GFR -RET –signalling, evidence exists that RET recruits different 
intracellular adaptor proteins outside lipid rafts than inside the rafts (Paratcha et al., 2001). 
This comprehensive study by Paratcha et al. (2001) describes a plethora of options for GDNF- 
GFR 1-RET –signalling. It was shown that GDNF-GFR 1 –complex can activate RET even if it is 
not  located  on  the  same cell,  but  in  soluble  form,  bound to  another  cell,  or  immobilized  in  
extracellular matrix. Also, RET is attracted to lipid rafts by both membrane-bound and soluble 
GDNF-GFR 1 –complexes, of which latter triggers sustained RET signalling. These findings 
offer an explanation to how GFL –signalling is organized in cells and tissues that express GFR  
receptors but not RET. Various intracellular signalling pathways are activated by RET. These 
include MEK/MAPK, PI3K/Akt and PLC , which are also activated by neurotrophins 
(Airaksinen and Saarma, 2002).  
In addition to GFR -RET –receptor complexes, other signalling receptors have been identified 
for GFLs. In cells devoid of RET, GFR 1, -2 and -4 can associate with the neural cell-adhesion 
molecule (NCAM, specifically the NCAM-14o -isoform) and offer a high-affinity binding cite 
for the ligands (Paratcha et al., 2003). This activates the intracellular tyrosine kinases Fyn and 
FAK. Recently, a transmembrane heparan sulphate proteoglycan, syndecan-3, was described 
both as a signalling receptor and a presenting receptor for GFLs excluding persephin, which 
has the lowest affinity for heparin-like structures (Bespalov et al., 2011). The hypothetical 
model created on the basis of these experiments suggests that syndecan-3 concentrates GFLs, 
in the vicinity of their other signalling receptors. On the other hand, in the absence of the 
other receptors, syndecan-3 activates cytoplasmic Src-family kinase-signalling by immobilized 
(extracellular matrix-bound) GDNF. The discovery of syndecan-3 as a receptor for GDNF 
explains earlier findings demonstrating that in the absence of heparan sulphate structures, 
GDNF is unable to activate RET and therefore fails to induce typical morphological changes in 
midbrain cell cultures (Barnett et al., 2002). Finally, there is also interesting crosstalk between 
GDNF and Met receptor tyrosine kinase: in cultured kidney cells GDNF can indirectly and Src-
dependently activate Met, and in GABAergic cells Met-activation seems to negatively regulate 
GDNF-GFR 1-signalling (Popsueva et al., 2003, Perrinjaquet et al., 2011). The emergence of 
these new signalling receptors has at least partially helped in explaining the more widespread 
expression of GFR ’s in comparison to RET distribution. 
 





Figure  3.  GDNF  –family  ligands,  their  receptors  and  effects  on  neurons. GFLs function as 
dimers to activate their receptors. GFR  –coreceptors are GPI –linked on the cell membrane (apart 
from the two soluble isoforms) and interact with RET to form heterotetramers and trigger 
intracellular  signalling.  GFR 1  can  also  interact  with  NCAM.  Syndecan-3  is  a  heparan  sulphate  
proteoglycan, the latest receptor identified for GFLs. The preferred ligand for each GFR  is marked in 




Also of note, it has been shown that the neurotrophic activity of GDNF on variety of cultured 
peripheral and central nervous system neurons requires the presence of TGF-  (Krieglstein et 
al.,  1998).  It  is  believed that TGF-  helps to recruit  and cluster GFR 1 on the cell  membrane,  
most likely to the lipid rafts (Peterziel et al., 2002). This co-operation is a relevant 
phenomenon also in vivo, as it was confirmed in the MPTP –mouse model of PD (Schober et 
al.,  2007).  However,  this  co-operation  does  not  seem  to  be  essential  for  the  development  of  
DAergic neurons, since GDNF/TGF- 2 double knock-out mice do not show DAergic neuronal 
loss at late embryonic stage (Rahhal et al., 2009). Instead, deficits are found in motor, sensory 
and sympathetic neurons. Furthermore, GDNF/TGF- 2 double heterozygous knock-out mice 
do not develop nigrostriatal degeneration with age (Heermann et al., 2010). 
 
Neuronal populations and functions supported by GFLs 
Phenotypes of GFL knock-out mice have been extensively reviewed earlier, (Airaksinen and 
Saarma, 2002) and are only summarized here. GDNF, GFR 1 and RET are all crucially needed 
during development, and full knock-out mice die after birth because of severe organic defects. 




All of these signalling components are needed for normal development of kidneys and enteric 
nervous system (Schuchardt et al., 1994, Moore et al., 1996, Pichel et al., 1996, Sanchez et al., 
1996,  Enomoto  et  al.,  1998).  Enteric  neurons  below  stomach  are  missing  in  all  of  the  
aforementioned knock-out mice. Also some parasympathetic ganglia (otic and 
sphenopalatine)  are  absent  or  the  neurons  are  smaller  in  size  and  lesser  in  number  
(submandibular ganglion), and there is a loss of spinal and cranial motor neurons. Reduced 
soma size (DRG) and loss of sensory neurons (petrosal ganglion) is seen in mice lacking 
GDNF-GFR 1 -components, which manifests for example as respiratory difficulties in the 
heterozygous mice. Sympathetic neurons are affected as well by the absence of GDNF-GFR 1- 
RET-signalling, and especially in RET-deficient mice deficits are seen in practically all 
sympathetic neuronal populations. The creation of a conditional GDNF-null mouse revealed 
that if GDNF is abolished in the adult mouse nervous system, catecholaminergic neurons 
undergo extensive degeneration (Pascual et al., 2008). Such dramatic loss has never been 
found in traditional GDNF, GFR 1 or RET knock-out mice, which suggests that compensatory 
mechanisms take place in those animals, and that under normal physiological conditions 
GDNF is required for the maintenance of catecholaminergic neurons. Outside the nervous 
system, GFR 1 and GDNF are needed in the regulation of spermatogenesis (Meng et al., 2000).  
 
NRTN and GFR 2 knock-out mice are viable, but the latter grow poorly. They exhibit subtle 
defects of sensory neurons (DRG), but NRTN-GFR 2-signalling seems to be especially 
important for the correct development and maintenance of parasympathetic target 
innervation. A switch in GFL dependence seems to occur during parasympathetic 
development: initially GDNF is needed for migration and proliferation of precursor cells. 
Cholinergic innervation is reduced for example in the intestine, pancreas, heart, salivary and 
lacrimal glands, and some parasympathetic ganglia or neurons are smaller in size in NRTN or 
GFR 2 –deficient mice. A moderate loss of enteric neurons is also seen. ARTN and GFR 3-
deficient mice are viable, and the most striking phenotype of GFR 3 –knock-outs, similarly to 
RET -knock-outs, is severe sympathetic defect. ARTN-GFR 3-RET -signalling seems to be 
essentially required for migration and axon growth during the development of sympathetic 
innervation. Interestingly, also during the development of sympathetic neurons, the initially 
required ARTN –signalling (for proliferation of precursors, migration and initial neurite 
outgrowth), is switched to a later dependence on neurotrophins to maintain target 
innervation. PSPN and GFR 4-knock-out mice are viable and show no gross defects, although 
it has been reported that GFR 4 -deficient mice have impaired thyroid calcitonin production 
(Tomac et al., 2002, Lindfors et al., 2006). 
Essentially,  the  aforementioned  neural  populations  are  supported  by  GFLs  in  in vitro 
conditions,  but  the  list  can  be  made  even  longer.  For  example,  GDNF  supports  the  survival  
and differentiation of cerebellar Purkinje cells, all of the ligands support the survival of 
GABAergic primary neurons and DAergic neurons (PSPN being less potent than the others), 
and all ligands but ARTN promote the survival of serotonergic primary neurons (Mount et al., 
1995, Baloh et al., 1998, Horger et al., 1998, Åkerud et al., 2002, Ducray et al., 2006). 
On top of the important functions of GFLs during development of different neural 
populations,  they  have  further  roles  in  adult  nervous  system.  For  example,  GDNF  seems  to  




reduce psychostimulant and alcohol reward, as reviewed by Ghitza et al., 2010. Heterozygous 
GDNF –knock-outs have impaired learning performance in the water maze paradigm, and 
GFR 2 –knock-out mice show memory deficits in several experimental setups (Gerlai et al., 
2001, Võikar et al., 2004). GDNF is also associated with formation of synapses, enhancement of 
neurotransmitter release and thus, synaptic strengthening (Wang et al., 2001, Ledda et al., 
2007). 
 
GDNF and the nigrostriatal DAergic pathway 
GDNF  is  one  of  the  most  potent  NTFs  for  DAergic  neurons  and  its  signalling  machinery  is  
present on these neurons.  In the adult  brain,  mRNAs of  RET and GFR 1 are abundantly and 
GFR 2 to a lesser extent expressed on the SNpc DAergic cell bodies, and RET seems to be 
transported to striatal afferents of these cells as well (Nosrat et al., 1997, Widenfalk et al., 1997, 
Golden et al., 1998, Hirata and Kiuchi, 2007). GFR 1 is found in the striatum, where GFR 2 is 
virtually absent (Widenfalk et  al.,  1997,  Kozlowski et  al.,  2004).  It  seems though, that striatal  
GFR 1 is not present on DAergic projections. Reports concerning the location of other GFL 
receptors in the nigrostriatal neurons were not found in literature search. 
GDNF is retrogradely transported in the DAergic neurons, and its possible function as a 
target-derived NTF is supported by the expression of its mRNA in striatal medium sized 
neurons both during development and adulthood (Tomac et al., 1995, Bizon et al., 1999, 
Kawamoto et al., 2000, Oo et al., 2005). Although virtually no defects have been found in the 
nigrostriatal DAergic system in young GFL, GFR - or RET-knock-out animals, there are 
interesting in vivo data  pointing  out  that  GDNF  indeed  is  a  target-derived  NTF  for  the  
developing DAergic system. DAergic neurons in postnatal rodents undergo developmental 
neuronal death, peaking immediately after birth and again two weeks later. Oo et al. (2003) 
have  shown  that  an  intrastriatal  injection  of  GDNF  at  the  time  of  the  first  peak  can  
significantly suppress natural cell death, and GDNF –neutralizing antibodies can augment it. 
In  a  further  study,  overexpression  of  GDNF  in  the  striatum,  cortex  and  hippocampus  could  
also prevent DAergic neuronal death during the first peak of apoptosis, althoughthe effect did 
not persist  to adulthood (Kholodilov et  al.,  2004).  Instead,  higher cell  numbers were seen in 
the ventral tegmental area (VTA) in adult mice, which suggests that the fate of nigrostriatal 
and mesolimbic DAergic neurons can be differently regulated by GDNF. As already 
mentioned, GDNF –signalling is pivotal in maintaining catecholaminergic neurons in the 
adult  nervous  system  (Pascual  et  al.,  2008).  Similarly,  aged  heterozygous  GFR 1-  or  GDNF-
deficient mice as well as conditional RET-knock-out mice show degenerative changes in their 
nigrostriatal DAergic neurons, which further emphasizes the role of GDNF in the maintenance 
of these neurons (Boger et al., 2006, Kramer et al., 2007, Zaman et al., 2008) 
When administered into intact nigrostriatal pathway, GDNF can augment DAergic function. A 
single intrastriatal injection of GDNF is able to induce sprouting of TH-positive fibres, 
increase DA turnover in the striatum (usually accompanied by decreased DA levels) and 
elevate nigral DA concentrations (Hudson et al., 1995, Hebert et al., 1996, Cass et al., 1999). In 
a later study, similar administration of GDNF lead to augmented D-amphetamine and K+ -
stimulated DA release (Hebert et al., 1996). The dopaminotrophic actions also manifested as 




increased spontaneous and D-amphetamine-induced locomotor activity in rats. These effects 
in vivo may be explained by specific findings in vitro:  GDNF can increase DA uptake and the 
amount of DA released, upregulate the expression of TH and increase the phosphorylation of 
TH (Lin et al., 1993, Pothos et al., 1998, Xiao et al., 2002, Kobori et al., 2004).  
Less  is  known  of  how  the  other  GFLs  affect  the  nigrostriatal  DAergic  system.  However,  
similarly to GDNF, intranigral  delivery of  NRTN increases striatal  DA turnover in intact rats,  
although DA levels get reduced (Cass and Peters, 2010a). Also, nigral DA concentrations were 
elevated, and D-amphetamine-induced DA overflow is increased. In aged rhesus monkeys, in 
which  the  DAergic  system is  already  naturally  compromised,  expression  of  NRTN by  AAV2-
vector in the caudate-putamen (CPu) increases 18F-fluorodopa  uptake  (CPu)  and  TH-
immunoreactivity (CPu and SN) (Herzog et al., 2007). 
 
Efficacy of GDNF in the 6-OHDA –model 
The effects of GDNF have been extensively studied in the 6-OHDA –model of PD, utilizing 
various methods of delivery (Tables 3-7). Unquestionably, GDNF has potent effects on the 
injured DAergic system even as a single injection. Generally, the most consistent finding in 
neuroprotection experiments (i.e. GDNF is administered before 6-OHDA) is that the DAergic 
function and connections are most effectively spared if both GDNF and 6-OHDA are 
administered into the striatum (Shults et al., 1996, Aoi et al., 2000c, Kirik et al., 2000a, Aoi et 
al.,  2001).  Moreover,  if  GDNF is  delivered  into  the  SN in  a  partial  lesion  model,  the  DAergic  
cell bodies are robustly protected but it is not enough to maintain striatal innervation (Sauer 
et  al.,  1995,  Kirik  et  al.,  2000a,  Rosenblad  et  al.,  2000).  GDNF also  induces  sprouting  of  TH-
positive fibres locally at the administration site, and in the globus pallidus. 
Some reports describe a higher preservation of striatal DA in cases when both the treatment 
and  the  toxin  were  given  to  the  SN,  but  the  striatal  innervation  was  not  studied  by  
immunohistochemistry (Kearns et al., 1997, Sullivan et al., 1998, Fox et al., 2001). Therefore, it 
is not clear whether the higher amount of DA in the striatum is due to higher levels of DA in 
remaining nerve terminals or due to increased survival or sprouting of DAergic terminals. 
Neuroprotection studies including measurement of nigrostriatal DA are surprisingly few, but 
the findings are consistent. Also, studies with behavioural assessment are rather few, and the 
results vary although it seems that whenever GDNF and 6-OHDA are injected into the same 
location, at least drug-induced rotational bias is ameliorated (Shults et al., 1996, Sullivan et al., 
1998, Aoi et al., 2000c, Kirik et al., 2000a, Aoi et al., 2001). 
Results from the neurorestoration experiments (i.e. GDNF is given after 6-OHDA –lesioning) 
are perhaps less uniform, but some general conclusions can be drawn. Positive changes in 
striatal  TH-immunoreactivity  are  seen  again  only  if  GDNF  and  6-OHDA  are  both  given  
intrastriatally (Aoi et al., 2000a, Aoi et al., 2000b, Aoi et al., 2001). In the studies by Kirik et al. 
(2001), this correlation was not seen, which could be explained by the substantial lesion that 
was employed. Also, it is curious that sequential administration of GDNF to any brain area in 
the partial lesion model seems to be rather ineffective in the neurorestoration paradigm: 
protection of nigral cell bodies or DA content is usually seen, but without positive striatal 
changes or reduction of rotational bias (Rosenblad et al., 1998, Rosenblad et al., 1999). 




Intranigral GDNF combined with intranigral lesion generally has regenerative effects that are 
confined to the SN, but which is accompanied by reversal of rotational bias (Hoffer et al., 1994, 
Bowenkamp  et  al.,  1995,  Bowenkamp  et  al.,  1997).  Intracerebroventricular  delivery  of  GDNF  
has  similar  effects  as  intranigral  delivery  in  a  partial  lesion:  recovery  is  seen  only  in  the  SN,  
and there are positive behavioural  effects in PD rats (Lapchak et  al.,  1997b,  Rosenblad et  al.,  
1999, Kirik et al., 2001).  
Regarding possible clinical applications, multiple or continuous intracerebral injections of 
trophic factors into the brain are a tedious and an inconvenient way to deliver the therapeutic 
protein. Therefore, it has been of interest to develop delivery systems that would provide long-
term release or production of the NTFs. There appears to be three main approaches with 
GDNF: a) transfected cells that produce and release the protein, b) synthetic polymer 
materials  that  release  growth  factors  and  c)  transfection  of  host  cells  by  viral  vectors  for  
endogenous overexpression and release of the trophic factor. Results arising from experiments 
using these approaches are summarized in tables 5-7. 
In general, sustained GDNF release by cell or polymer preparations has been effective in both 
neuroprotection and neurorestoration paradigms (Table 5). All of these experiments have 
been based on a partial 6-OHDA –lesion. In the neuroprotection studies, intrastriatally 
implanted GDNF-secreting neural stem cells, astrocytes and encapsulated baby hamster 
kidney cells (BHK) could significantly protect nigral TH-positive cells and their striatal fibers 
(Åkerud et al.,  2001,  Cunningham and Su,  2002,  Yasuhara et  al.,  2005b).  However,  Ericson et  
al.  (2005) reported that GDNF-producing astrocytes could only protect nigral  TH-cell  bodies 
but  not  striatal  connections  when  implanted  into  the  SN,  and  striatal  implantation  was  
completely inefficient. It is possible, that these astrocytes did not produce sufficient amounts 
of  GDNF,  although  it  was  detected  by  immunohistochemistry  in  the  brain  tissue.  All  in  all,  
these results are in line with those obtained with GDNF protein injections, although the local 
concentrations of GDNF most likely remain lower with sustained-release delivery systems. 
Importantly, no severe adverse effects were reported. 
The results from neurorestoration experiments have been encouraging as well. GDNF-
releasing human bone marrow cells, encapsulated BHK-cells, fibroblasts and polymeric 
microspheres could all induce behavioural recovery (i.e. reversal of rotational bias), and 
increase striatal DA or TH-innervation (Jollivet et al., 2004a, Jollivet et al., 2004b, Duan et al., 
2005, Yasuhara et al., 2005b, Garbayo et al., 2009, Glavaski-Joksimovic et al., 2010). Nigral TH-
cells were not rescued with polymeric microspheres, though it was not measured in the study 
by Garbayo et al. (2009). Still, it seems that the microspheres were capable of releasing enough 










Table 3.  Neuroprotection experiments with GDNF in the 6-OHDA –rat model of  PD. Table 
includes summaries of behavioural changes, protection of striatal DA and nigral or striatal TH-
immunoreactivity from experiments in which GDNF protein has been delivered as injections or via 
minipump before (or less than 24 h after) 6-OHDA. Table organized according to elevating GDNF 
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AMPH= amphetamine-induced rotational behaviour, APO= apomorphine –induced rotational 
behaviour, DAT=dopamine transporter, FA= forelimb akinesia, GP= globus pallidus, ICV= 
intracerebroventriculartly, MFB= medial forebrain bundle, PET=positron emission tomography, 
SN=substantia nigra, STR=striatum. Responses of GDNF-treated animals vs. lesion control animals: 
0=no change, = increased, =decreased n.m.= not measured. 
 




Table 4. Neurorestoration experiments with GDNF in the 6-OHDA –rat model of PD. Table 
includes summaries of behavioural changes, protection of striatal DA and nigral or striatal TH-
immunoreactivity from experiments in which GDNF protein has been delivered as injections or via 
minipump after 6-OHDA. Table organized according to elevating GDNF dosage. GDNF and 6-
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AMPH= amphetamine-induced rotational behaviour, APO= apomorphine –induced rotational 
behaviour, DAT=dopamine transporter, FA= forelimb akinesia, ICV= intracerebroventriculartly, MFB= 
medial forebrain bundle, SN=substantia nigra, STR=striatum. Responses of GDNF-treated animals vs. 
lesion control animals: 0=no change, = increased, =decreased n.m.= not measured. 
 
 




Table 5. Effects of sustained delivery of GDNF in neuroprotection and neurorestoration in 
the  6-OHDA  –models  of  PD.  Table includes summaries of behavioural changes, protection of 
striatal DA and nigral or striatal TH-immunoreactivity from experiments in which GDNF protein 
has been administered via sustained delivery systems before or after 6-OHDA –lesioning. GDNF 
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AMPH= amphetamine-induced rotational behaviour, APO= apomorphine –induced rotational 
behaviour, BHK-cells=baby hamster kidney cells, DAT=dopamine transporter, ICV= 
intracerebroventriculartly, MFB= medial forebrain bundle, SN=substantia nigra, STR=striatum. 
Responses of GDNF-treated animals vs. lesion control animals: 0=no change, = increased, 








There is extensive evidence, that GDNF -gene delivery is effective in protecting nigrostriatal 
DAergic neurons against 6-OHDA -toxicity in the partial lesion model. All reports describe an 
increase  in  the  survival  of  TH-positive  cells  in  the  SN  regardless  of  the  vector  used  or  the  
location of vector delivery. In only one study there was a lack of nigral recovery, but this was 
measured as TH mRNA, and could be attributed to the fact that long-term delivery of GDNF 
can downregulate TH in the nigrostriatal DAergic neurons (Rosenblad et al., 1999, Connor, 
2001, Georgievska et al., 2004). Similarly to GDNF protein delivery, its gene expression in SN 
only is often not sufficient to protect striatal connections or prevent behavioural deficits 
(Connor et al., 1999, Kirik et al., 2000b). Still, Chen et al. (2003) and Connor et al. (2001) have 
reported of a higher striatal DA concentration or DAT –radioligand binding in comparison to 
control animals, but these effects were not accompanied by reversal of rotational bias. 
Conversely,  Bensadoun  et  al.  (2000)  showed  that  in  the  abscence  of  striatal  DAergic  
protection, apomorphine -induced rotations are reduced in mice. Surprisingly, striatal gene 
delivery is very efficient in improving behavioural measures, although striatal recovery is only 
seldom seen. This lack of striatal recovery, if measured as expression of TH, may not be a 
reliable measure because of its downregulation as already mentioned. 
In the neurorestoration paradigm, the results of intrastriatal GDNF-vector delivery in partial 
lesion models are fairly consistent. Either striatal or nigral recovery, or both, of DA or TH-
innervation is observed, and accompanied by behavioural improvements (Lapchak et al. 1997a, 
Wang et al.,  2002,  Zheng et  al.,  2005,  Brizard et  al.,  2006).  In the studies by Kozlowski et  al.  
(2000), however, intrastriatal delivery of adenoviral GDNF was totally inefficient. Intranigral 
administration of vectors seems to have local dopaminotrophic actions that do not extend to 
the striatum, which is typical to the delivery of recombinant GDNF as well. 
The variation in the experiments with viral vectors may be explained by several factors. Firstly, 
the amount of vector injected varies between the experiments. Secondly, the transfection 
efficacy of the viral vectors may differ, and thirdly, the vectors can preferentially transfect 
different cell populations. Whether it is essential to transfect nigrostriatal DAergic cells, or 
whether it is sufficient to transfect other cell populations around DAergic cells to offer trophic 
support from outside the nigrostriatal pathway, seems unsolved.  
As a general conclusion, despite some discrepancies between studies utilizing various methods 
of delivery, GDNF has shown great potential as a therapeutic molecule for PD as assessed in 
the 6-OHDA –model. When a total lesion is employed, it is still possible to achieve at least 
local nigral recovery and behavioural recovery if GDNF is delivered into the SN. In a partial 
lesion model, GDNF –treatment is most effective when given intrastriatally. The observations, 
that behavioural recovery is possible without significant positive changes in striatal TH-
innervation  or  DA  content  when  compared  to  control  treatment  can  be  due  to  the  
“pharmacological  effect”  of  GDNF,  i.e.  its  ability  to  boost  DA  turnover  and  augment  








Table 6. Neuroprotection experiments utilizing GDNF delivery via viral vectors in the 6-
OHDA  –models  of  PD.  Table includes summaries of behavioural changes, protection of striatal 
DA and nigral or striatal TH-immunoreactivity from experiments in which GDNF –vectors have 
been administered before 6-OHDA.  Table  organized  according  to  type  of  vector  used.  GDNF  –
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AAV=adeno-associated virus, AMPH= amphetamine-induced rotational behaviour, APO= apomorphine 
–induced rotational behaviour, CT= cylinder test, DAT=dopamine transporter, FA= forelimb akinesia, 
GFAP=glial fibrillary acidic protein, GP= globus pallidus, HSV-1= Herpes Simplex 1,  ICV=  
intracerebroventriculartly, MFB= medial forebrain bundle, SN=substantia nigra, STR=striatum. 
Responses of GDNF-treated animals vs. lesion control animals: 0=no change, = increased, 
=decreased n.m.= not measured. 
 
Table 7. Neurorestoration experiments utilizing GDNF delivery via viral vectors in the 
6-OHDA  –rat  model  of  PD.  Table  includes  summaries  of  behavioural  changes,  protection  of  
striatal DA and nigral or striatal TH-immunoreactivity from experiments in which GDNF –vectors 
have been administered after 6-OHDA. Table organized according to type of vector used. GDNF –
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AAV=adeno-associated virus, AMPH= amphetamine-induced rotational behaviour, APO= apomorphine 
–induced rotational behaviour, CT= cylinder test, DAT=dopamine transporter, SN=substantia nigra, 
STR=striatum. Responses of GDNF-treated animals vs. lesion control animals: 0=no change, = 
increased, =decreased n.m.= not measured. 
 
Studies of NRTN and PSPN in the 6-OHDA –model of PD 
Other GFLs than GDNF have been much less studied in preclinical  models of  PD. There is  a  
handful of neuroprotection and neurorestoration studies each done with NRTN, in which 
various methods of delivery have been used in a partial lesion model in rats. There are no 
studies available concerning artemin, and only one report describing the effects of PSPN. In 
this one study, neural stem cells were engineered to express and secrete PSPN and grafted to 
four striatal locations in mice two weeks before striatal 6-OHDA (Åkerud et al., 2002). PSPN 
treatment could significantly prevent the death of TH-positive cells in the SN and reduce 
amphetamine-induced rotational behaviour. 




Taken together, neuronal protection in the SN has been observed in all neuroprotection 
studies with NRTN, whereas maintenance of striatal innervation has not been as consistent. In 
both studies, in which NRTN protein was given as a single intrastriatal 5 µg injection 1-3 days 
before 6-OHDA, elevated post mortem striatal DA concentrations were observed (Oiwa et al., 
2002, Cass and Peters, 2010b). Oiwa et al. (2002) also reported a reduction in amphetamine-
induced rotations. In the study by Cass et al. (2010b) potassium- or amphetamine–induced DA 
release in the striatum was improved with NRTN as measured by microdialysis. 
Rather surprisingly, when NRTN has been delivered intrastriatally for longer periods starting 
14-15 days before 6-OHDA-lesioning, it has been ineffective in preserving striatal TH-fibres or 
DA, despite protection of nigral cells. Nevertheless, in two studies, utilizing NRTN-expressing 
neural stem cells or an AAV-vector –mediated delivery, reduced rotational behaviour was 
observed (Gasmi et al., 2007, Liu et al., 2007). The positive effect by AAV-NRTN (CERE-120) on 
nigral TH-cells was further confirmed by Bartus et al., 2011. Lentiviral expression of modified 
or wild-type (WT) NRTN did not lead to behavioural improvement (Fjord-Larsen et al., 2005). 
WT NRTN was without any protective effects in the studies, whereas the immunoglobulin 
signal peptide –conjugated modified NRTN could protect TH-positive cells, and was also 
retrogradely transported from the striatum to the SN. Of note, Gasmi et al. (2007) detected a 
significant protection of striatal vesicular monoamine transporter immunoreactivity by AAV-
NRTN,  which  could  mean  that  NRTN  either  downregulates  TH  or  does  not  support  the  
maintenance of TH-phenotype in nigrostriatal DAergic neurons. Indeed, Rosenblad et al. 
(1999) observed a reduction in the intensity of TH-expression in surviving nigral neurons in 
NRTN –treated and 6-OHDA –lesioned rats, and therefore TH may not be a reliable marker of 
DAergic cells and their projections in studies with NRTN. 
Results of neurorestoration studies are rather inconsistent. Generally, a single administration 
of NRTN has been more effective than long-term delivery in the partial lesion model, as it was 
in the neuroprotection studies as well. Oiwa et al. (2002) reported of an amelioration of 
rotational bias accompanied by elevated striatal TH and DA levels after 5 µg of intrastriatal 
NRTN, although it was delivered as late as 12 weeks post lesioning. Horger et al. (1998) 
analysed only the survival of nigral DAergic cells, and found that an intranigral injection of 10 
µg of NRTN one week after lesioning was sufficient to reduce neurodegeneration. 
Interestingly,  in  the  same  study,  altogether  8x5  µg  of  NRTN  given  to  the  SN  increased  the  
survival  of  nigral  neurons,  but  not  their  TH-phenotype.  This  is  in  line  with  Rosenblad  et  al.  
(1999) who used the same delivery regime as Horger et al. (1998), but delivered NRTN into the 
striatum or lateral ventricle. Only striatal delivery could significantly protect nigral cell bodies, 
but no behavioural or striatal recovery was detected. Striatal NRTN delivery via transduced 
bone  marrow  stromal  cells  three  weeks  after  an  extensive  6-OHDA  lesion  of  the  MFB  and  
VTA, was ineffective (Ye et al., 2007). 
In conclusion, NRTN and PSPN have been demonstrated to have positive therapeutic effects 
in 6-OHDA –treated rats although the correlations of behavioural, striatal and nigral 
recoveries  are  not  very  consistent  with  NRTN.  Lack  of  reports  concerning  ARTN  and  PSPN  
may imply though, that there are a lot of unpublished negative data, which would not support 
a possible therapeutic role for these ligands in the treatment of PD. Also, it has been a matter 




of discussion how NRTN induces the positive effects seen in the 6-OHDA –experiments, as 
there is virtually no GFR 2 in the striatum, and its expression is rather decreased, if changed 
at all by 6-OHDA –lesions (Marco et al., 2002, Kozlowski et al., 2004). However, since NRTN 
can also bind to GFR 1 (though not preferentially), it is probably at least one of the mediators 
of the effects. 
 
2.3.3 CDNF/MANF –family of NTFs 
Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived 
neurotrophic factor (MANF), both of which are widely expressed in mammalian tissues, are so 
far  the  only  known  members  of  an  evolutionarily  conserved  family  of  NTFs  (Lindholm  and  
Saarma, 2010). A structural peculiarity of these proteins is that they contain eight cysteine 
residues,  which  can  be  found  in  all  the  protein  homologues  in  both  vertebrates  (CDNF  and  
MANF) and invertebrates (only MANF homologue). Also unique to these proteins, the 
mammalian CDNF and MANF consist of an N-terminal saposin-like domain and a c-terminal 
domain with cystein bridges (Parkash et al., 2009). The signalling receptors for these NTFs 
have not yet been identified, but their roles as extracellularly functioning NTFs is supported 
by observations that both proteins seem to be secreted by transfected cells (Lindholm et al., 
2007,  Apostolou  et  al.,  2008,  Lindholm  et  al.,  2008).  However,  MANF  and  CDNF  are  also  
retained in the endoplasmic reticulum (ER) (Apostolou et al., 2008). MANF gene and protein 
expressions are induced by ER stress, and it can protect cells against ER-stress –induced death, 
which may be a common mechanism of neuroprotection for the proteins (Lee et al., 2003, 
Mizobuchi et  al.,  2007,  Apostolou et  al.,  2008,  Tadimalla et  al.,  2008,  Yu et  al.,  2010).  Also,  a  
recent article describes the ability of intracellular MANF to inhibit Bax-dependent apoptosis in 
neurons (Hellman et al., 2011). 
MANF was the first member of the family to be discovered as a NTF, although it was already 
earlier known as “arginine-rich, mutated in early stage tumors” or arginine-rich protein, 
expressed  by  various  tumours.  MANF was  detected  in  the  culture  medium of  a  rat  astrocyte  
cell line, and was shown to protect DAergic neurons rather selectively (Petrova et al., 2003). 
Since then, it has been demonstrated that MANF expression is induced in neurons and glial 
cells  in  an  experimental  model  of  brain  ischaemia  (Lindholm  et  al.,  2008,  Yu  et  al.,  2010).  
Furthermore, intracortical pretreatment with recombinant MANF or expression of MANF via 
AAV-vector can reduce the size of infarction and promote motor recovery in rats after middle 
cerebral artery occlusion (Airavaara et al., 2009, Airavaara et al., 2010). These studies describe 
a reduction in TUNEL –expressing neurons both in in vitro and in vivo conditions of hypoxia. 
Thus far, our knowledge of neuroprotective and neurorestorative actions of CDNF is limited to 
models of PD only. 
Both MANF and CDNF have been studied in the partial 6-OHDA lesion model of PD in rats. 
The first report on the discovery of CDNF also describes robust neuroprotective and 
neurorestorative effects on both behavioural and morphological levels (Lindholm et al., 2007). 
The study showed that D-amphetamine –induced ipsilateral turning was significantly reduced 
already with 3 µg of CDNF, and that the nigrostriatal DAergic neurons were preserved at least 
to  the  same  extent  as  with  GDNF.  In  similar  experimental  setups  as  used  for  CDNF,  MANF  




could also effectively reverse the rotational bias (Voutilainen et al., 2009). In the 
neuroprotection experiment, TH-positive cells in the SNpc were effectively spared by MANF, 
but this protective effect was not seen in the striatal terminal area. In the neurorestoration 
setup, MANF was even more potent than GDNF in reducing rotations, but without significant 
effect on the survival of TH-positive cells. In support of CDNF being perhaps the more potent 
member of the family, at least when assessed in the 6-OHDA rat model of PD, the latest study 
in this field showed that a two-week minipump-infusion of CDNF could significantly reduce 
rotational behaviour in rats lesioned two weeks before the start of the infusion (Voutilainen et 
al., 2011). Also, the nigrostriatal DAergic cells and connections were well spared. MANF, 
however, was not effective in a similar experiment.  
To date, the neuroprotective and neurorestorative effects of CDNF have been examined only 
in one study employing in MPTP mouse model of PD (Airavaara et al., 2011). The results of the 
study  were,  in  all,  the  same  as  in  the  6-OHDA  rat  model,  and  support  the  opportunity  of  
exogenous CDNF as a novel neurotrophic treatment against DAergic neurodegeneration. 
In the pursuance of the 6-OHDA studies, the distribution patterns of exogenously applied 
CDNF  and  MANF  were  studied  (Voutilainen  et  al.,  2009,  Voutilainen  et  al.,  2011).  The  
distribution of CDNF after a single intrastriatal injection seems to largely resemble that of 
GDNF,  including  retrograde  transport  to  the  SN.  MANF,  on  the  other  hand,  seems  to  be  
relocated towards frontal cortical areas. Also, MANF is more readily distributed in the brain 
tissue  at  the  early  stages  of  a  chronic  infusion,  when  compared  to  CDNF  and  GDNF.  The  
different distribution pattern of MANF may be beneficial if the molecule is to be considered 
for clinical use, since it has been speculated that one of the pitfalls in clinical trials with 
recombinant GDNF was its poor diffusion in the brain. 
 
2.3.4 VEGF-family ligands 
Evidence suggests that vascular defects and impaired blood circulation may significantly 
contribute to a variety of neurodegenerative diseases (Zlokovic, 2011). For example, the 
breakdown of  the  BBB leads  to  cerebral  accumulation  of  substances  that  can  cause  oedema,  
direct neurotoxicity and generation of reactive oxygen species (eg. iron from red blood cells). 
Hypoperfusion and hypoxia lead to decreased protein synthesis, impaired activity of 
transporter proteins, failure in ion gradient maintenance and abnormal generation of action 
potentials. This may ultimately lead to oedema and lesions. Also, the metabolic profile in the 
vascular endothelium can change, and both toxic and inflammatory factors may be secreted to 
the brain tissue. Even normal aging is associated with disruption of the BBB and diminished 
brain blood circulatory functions. Of neurodegenerative diseases, cerebrovascular dysfunction 
is most extensively described in AD, but seems to play a part also in PD, amyotrophic lateral 
sclerosis (ALS), multiple sclerosis, and Huntington’s disease. In this context, it may be of 
importance to study growth factors that affect the vascular system and have direct protective 
effects on neurons as possible therapeutic molecules for neurodegenerative disorders.   
 




Overview of VEGF-family ligands and receptors 
VEGF family is comprised of  VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor 
(PlGF),  which are found in mammals,  and VEGF-E coded by the orf virus,  as well  as VEGF-F 
from  snake  venom.  Several  of  the  family  members  are  expressed  in  many  isoforms  due  to  
alternative splicing or post-translational processing, which also alters their receptor specificity 
(Roy et al., 2006). There are three transmembrane tyrosine kinase receptors (VEGFR-1-3, 
Fig. 4), which upon binding the dimeric ligands generally form homodimers, but VEGFR-2 can 
also heterodimerize. Furthermore, VEGFR-1 and VEGF-2 are expressed as soluble monomeric 
forms, which can antagonise the effects of their ligands. VEGFR-1 also has a unique property of 
being up-regulated by hypoxia (Kendall and Thomas, 1993, Marti and Risau, 1998, Ebos et al., 
2004, Tammela et al., 2005). VEGFs utilize neuropilins 1-2 (NRP1-2) as co-receptors. They are 
best known as receptors for class 3 semaphorins that have key roles in axonal guidance (Pellet-
Many et al., 2008). Interaction with the co-receptors, as well as the formation of heterodimers 
from  the  tyrosine  kinase  receptors,  leads  to  eg.  increase  in  receptor  affinity  for  ligands,  
augmented signal transduction or altered downstream signalling (Lohela et al., 2009). The 
principal effects of VEGF-family ligands are to induce and maintain angiogenesis and 
lymphangiogenesis during embryonal development and in adult during various physiological 
and pathological processes. These include wound healing, ocular neovascularisation, 
endometriosis, cardiovascular disease, and tumour (lymph)vascularisation and metastasis.  
On the basis of their main physiological functions, the mammalian VEGF-family ligands can 
be  roughly  divided  into  angiogenic  factors  or  modulators  (VEGF-A,  B  and  PlGF),  and  
lymphangiogenic factors (VEGF-C and –D) (Lohela et al., 2009). VEGF-A is one of the most 
potent angiogenic factors with a crucial role in the embryonic development of blood 
vasculature. Both knock-out mice of VEGF-A and VEGFR-2 have an embryonic lethal 
phenotype (Shalaby et al., 1995, Carmeliet et al., 1996, Ferrara et al., 1996). VEGF-A stimulates 
proliferation, migration and survival of endothelial cells, induces vasodilatation and increases 
vascular permeability, mostly via VEGFR-2. In addition, it induces migration of hematopoietic 
stem cells and recruitment of inflammatory cells, probably via VEGFR-1. VEGF-A is also 
strongly induced in hypoxia, and it is expressed in various kinds of tumours and malignancies 
(Tammela et al., 2005, Roy et al., 2006). VEGF-B and PlGF, on the other hand, do not seem to 
be pivotal in embryonic vascular development. Instead, they seem to have angiogenic actions 
through VEGFR-1 under pathological conditions like inflammation and ischaemia, and 
especially the angiogenic effects of VEGF-B are rather weak under most circumstances (Lohela 
et al., 2009). VEGF-B has also been implicated in heart development and coronary vessel 
formation,  and may even be considered as a survival  factor for blood vessels  (Bellomo et al.,  
2000,  Zhang  et  al.,  2009,  Bry  et  al.,  2010).  A  similar  division  can  be  made  with  the  
lymphangiogenic growth factors: VEGF-C is crucially required for the development of 
lymphatic  vessels  and  the  knock-out  mice  die  as  embryos,  whereas  this  is  not  observed  in  
VEGF-D knock-outs (Kärkkäinen et al., 2004, Baldwin et al., 2005, Koch et al., 2009). Both 
have active roles in the adult, also during inflammation and tumorigenesis. The growth of new 
lymphatic vessels is mediated through VEGFR-3, activation of which increases the 
mitogenesis, migration and survival of lymphatic endothelial cells. VEGF-C and D also cause 
vascular  leakage  and  can  induce  angiogenesis  via  VEGFR-2  (Roy  et  al.,  2006,  Lohela  et  al.,  
2009). 






Figure 4. VEGF-receptors and their ligands. Dimeric ligands bind to their receptors, which also 
become dimerized upon ligand binding, and intracellular tyrosine kinase domains are 
transphosphorylated. VEGFR-1 and VEGFR-2 are mainly involved in regulation of angiogenesis, 
mediating proliferation, migration and survival of endothelial cells, vasodilatation and increase of 
vascular permeability. Their soluble forms act antagonistically. VEGFR-3 signalling increases the 
mitogenesis, migration and survival of lymphatic endothelial cells. NRP –coreceptors interact with 
VEGFRs to modulate the signalling, and VEGFR-2 can dimerize also with the other two VEGFRs.  All 
three VEGFRs mediate specific effects in the nervous system, and also NRP1 likely has a role in VEGF-
A –induced neurite outgrowth. Figure adapted from Ruiz de Almodovar et al., 2009 and Zachary, 
2005.  
 
Connections of VEGF-A to neurological disorders 
VEGF-A  is  the  only  member  of  the  growth  factor  family  whose  association  to  neurological  
disorders has been extensively studied, despite lack of compelling evidence of the involvement 
of VEGF-A –related genetic variations in these diseases. In AD, VEGF-A levels are elevated in 
the cerebrospinal fluid (Tarkowski et al., 2002) and it is co-precipitated in the amyloid plaques 
typically  seen  in  AD  brains  (Yang  et  al.,  2004,  Ryu  et  al.,  2009).  Administration  of  VEGF-A  
seems beneficial in transgenic mouse models of AD (Spuch et al., 2010, Wang et al., 2011), and 
interestingly, -amyloid can antagonize VEGFR-2 signalling in vitro (Patel et al., 2010). In PD 




patients,  the  expression  of  VEGF-A,  and  in  many  cases  also  the  expression  of  VEGFR-1,  is  
increased in the SN, especially in reactive astrocytes (Wada et al., 2006). Concentration of 
VEGF-A in plasma is not changed in PD (Wada et al., 2006, Infante et al., 2007).  
In ALS,  changes in VEGF-A levels  in plasma or cerebrospinal  fluid have not been consistent,  
but a decrease in VEGF-A- and VEGFR-2-expressing motor neurons has been reported 
(Bogaert et al., 2006, Brockington et al., 2006). Also, a conclusive genetic link between VEGF-
A  and  the  human  disease  is  lacking,  although  there  are  reports  of  VEGF-gene  haplotypes  
associated with ALS (Bogaert et  al.,  2006,  Ruiz de Almodovar et  al.,  2009).  There is  stronger 
evidence from animal studies showing a connection between VEGF-A and ALS, as reduced 
expression  of  VEGF-A  via  deletion  of  the  hypoxia  response  element  in  the  promoter  of  the  
gene brings up an ALS –like phenotype in mice (Oosthuyse et al., 2001). Moreover, cross-
breeding these mice to another established mouse line modelling ALS (SOD1G93A)  leads  to  
aggravation of motor symptoms and earlier death of the mice in comparison to either mouse 
line with a single gene mutation (Lambrechts et al., 2003). Also, administration or 
overexpression of VEGF-A delays the onset of symptoms and prolongs survival in rodent 
models of ALS (Azzouz et al., 2004, Zheng et al., 2004, Storkebaum et al., 2005, Wang et al., 
2007). Finally, the ischaemic stroke is a condition in which it would be highly beneficial to 
restore  blood  supply  to  the  oxygen-deprived  areas  of  the  brain  as  well  as  to  provide  
neurotrophic support. VEGF-A and its receptors are upregulated in the ischaemic brain, but 
exogenous VEGF-A may not be a rational approach because it increases vascular permeability 
by  disrupting  the  BBB  (Rite  et  al.,  2007,  Beck  and  Plate,  2009).  These  effects  may  lead  to  
increased brain aedema and leakage of unwanted molecules and cells into the brain, which in 
turn will compromise recovery. 
 
Effects of VEGF-ligands on neurons and glia 
The effects of VEGF-A on various kinds of neurons have been widely studied and reviewed 
(summary  in  Table  8).  In  general,  studies  have  shown  that  VEGF-A  can  increase  neuronal  
survival, proliferation and neurite outgrowth. In addition, VEGF-A also promotes the 
proliferation and migration of  glial  cells.  Based on all  this  data,  it  is  likely that the effects of  
VEGF-A  on  neurons  are  mediated  both  directly  through  receptors  on  the  neurons,  and  
indirectly via activation of astroglia and induction of neovascularisation.  
Fairly little is known about the roles of other VEGF-family ligands in the nervous system so 
far. VEGF-B has been demonstrated to stimulate neurogenesis and to inhibit apoptosis in 
retinal ganglion cells and in the ischaemic brain. It also increases the survival of motor 
neurons and DRG sensory neurons as well as protects DAergic neurons against rotenone 
toxicity both in vitro and in vivo (Sun et al., 2006, Li et al., 2008, Poesen et al., 2008, Falk et al., 
2009, Dhondt et al., 2011). VEGF-C seems to have a crucial function in the developing nervous 
system, and it is required for the proliferation of neural progenitor cells as well as 
oligodendrocyte precursor cells of the optic nerve (Le Bras et al., 2006). It is also implicated in 
adult neurogenesis in the hippocampus and subventricular zone after cerebral ischaemia (Shin 
et  al.,  2008).  Recently,  Chaballe  et  al.  (2011)  found  that  the  proliferation  of  Schwann  cells  is  
reduced in primary cultures and in a model of Wallerian degeneration in PlGF knock-out 




mice. PlGF can also protect cultured cortical neurons against ischaemic damage, prevent 
growth cone collapse in DRG and alleviate diabetic sensory deficits in mice (Cheng et al., 
2004, Du et al., 2010, Murakami et al., 2011) . 
VEGFR-1 and VEGFR-2 are expressed widely throughout the developing rat brain (Yang et al., 
2003). In the adult rat brain, the expression levels are low, but the receptors have been found 
for example in cortical  and hippocampal neurons (Sondell  and Kanje,  2001,  Yang et  al.,  2003,  
Yasuhara  et  al.,  2004).  Since  VEGF-A  also  affects  other  neuronal  populations  (Table  8),  the  
receptors are most likely present on those neurons as well. According to recent reports, also 
VEGFR-3 mRNA is extensively found throughout the developing and adult rat brain (Choi et 
al., 2010, Hou et al., 2011a, Hou et al., 2011b). An interesting feature of VEGFRs is that they are 
upregulated by hypoxic or mechanical injuries to the brain (Marti and Risau, 1998, Krum et al., 
2002, Choi et al., 2007, Shin et al., 2008, Shin et al., 2010a, Shin et al., 2010b). 
Generally, the neuronal effects of VEGF-A are mediated via VEGFR-2, and the effects on glial 
cells via VEGFR-1 (reviewed by Ruiz de Almodovar et al., 2009). The activation of VEGFR-2 in 
the neurons can induce several signalling cascades, including the MEK/MAPK, PI3K/Akt, PLC  
and Rho/ROCK (Rho/Rho –associated protein kinase) –pathways. Also, VEGF-A can inhibit 
the activation of caspase-3, although it is not known which receptor mediates this effect (Jin et 
al., 2001, Sanchez et al., 2010). Furthermore, VEGF-A (and PlGF) can block the 
chemorepulsion, growth cone collapse and apoptosis caused by Sema3A in a neuronal cell 
culture via interaction with NRP1 (Bagnard et al., 2001). The downstream signalling pathways 
of  VEGFR-1  in  glial  cells  include  at  least  MEK/MAPK  and  PI3K/Akt  –cascades  (Mani  et  al.,  
2005).  
 
VEGF-B, on the other hand, induces its protective effects on neurons through VEGFR-1 (Li et 
al., 2008, Dhondt et al., 2011). This activates MAPK/ERK -signalling, and leads to reduced 
expression of cell-death related proteins and genes (Li et al., 2008). Knowledge of VEGF-C 
signalling in the nervous system is still very limited, but since both VEGFR-2 and VEGFR-3 are 
expressed (and can be induced) in the brain, it is likely that both receptors are mediating the 
effects. Le Bras et al. (2006) have shown that at least the proliferative effect of VEGF-C on 

















Table 8. Effects of VEGF-A on neuronal and glial cells. (Modified from Zachary, 2005, Ruiz de 
Almodovar et al., 2009, Wittko et al., 2009, Ruiz de Almodovar et al., 2010, Erskine et al., 2011)  
Cell type Effect (conditions) 
Central nervous system  
- cortical neurons (+E) 
- cholinergic neurons 
- granule cells 
- DAergic neurons (+E) 
- hippocampal neurons (+P) 
- motor neurons (+P) 
 
- retinal ganglion cells 
 
- astroglia 
- primary microglial culture 
 
 
survival after hypoxia, neurite outgrowth 
survival after NMDA stimulation 
migration 
survival against 6-OHDA 
survival after NMDA stimulation or hypoxia 
survival after hypoxia, hypoglycaemia and AR- 
polyglutamine toxicity 




Peripheral nervous system 
- DRG neurons 
- SCG neurons 
 
- Schwann cells (+P) 
 
 
survival, neurite outgrowth 
survival, neurite outgrowth 
 
survival, proliferation, migration 
Neural progenitors / SCs 
- cortical neuron precursors 
- SCG neural progenitors 
- SVZ neural progenitors 




proliferation, differentiation, migration 
proliferation, migration, survival 
+E=also embryonic; +P=also primary cultured neurons; DRG= dorsal root ganglion; NMDA= N-
methyl-D-aspartate, SC=stem cell, SCG=superior cervical ganglion, SVZ=subventricular zone 
 
Effects of VEGF-ligands in toxin-based models of PD 
VEGF-A, and -B are the only ligands of the VEGF-family that have been studied in 
experimental models of PD, and all of them have shown neuroprotective or neurorestorative 
potential. The first report by Yasuhara et al. (2004) described the neuroprotective effects of 
encapsulated baby hamaster kidney (BHK) cells expressing VEGF-A against 6-OHDA -toxicity 
in cultured primary midbrain neurons and in rats. In vitro,  VEGF-A  reduced  the  number  of  
apoptotic neurons and in the partially 6-OHDA –lesioned rats it significantly reduced 
amphetamine-induced rotational behaviour and protected TH-positive neurons and their 
projections. Later, the same group showed that low doses of VEGF-A are more efficient in 
neuroprotection (1 ng/ml in vitro, max. 11 ng/day secreted by capsules in vivo) than higher 
doses (10 or 100 ng/ml in vitro, max. 37 ng/day secreted by capsules in vivo) (Yasuhara et al., 
2005c). A natural continuum after neuroprotection experiments was to examine the 
neurorestorative effects of VEGF-A in the same in vitro and in vivo models. Indeed, Yasuhara 
et al. (2005a) demonstrated, that VEGF-A can rescue DAergic neurons also when administered 
after 6-OHDA. Other approaches in delivering VEGF-A into the rat brain to promote recovery 
in PD rats have been successful as well. Tian et al (2007) reported a neuroprotective effect of 
VEGF-A-expression by AAV-vector in 6-OHDA treated rats. The most recent study with 




rotenone-lesioned rats shows that grafted human umbilical cord mesenchymal stem cells 
expressing VEGF-A provide a more substantial functional and morphological recovery than 
control transplantation (Xiong et al., 2011). In addition, the differentiation of these cells into 
DAergic cells was enhanced by VEGF-A expression. 
Based collectively on the mechanistic results from the aforementioned studies, it can be 
concluded that VEGF-A most likely produces neuroprotection and neurorestoration through 
several direct or indirect mechanisms. Firstly, VEGF-A induces the formation of blood vessels 
around the administration site, which may enhance neurovascular coupling. However, this 
phenomenon combined with increased vascular permeability and BBB breakage can be 
difficult to control. Yasuhara et al. (2005c) have even speculated, that higher doses of VEGF-A 
are less effective than low doses because of brain aedema that deteriorates recovery. Secondly, 
VEGF-A administration increases the amount of glial fibrillary acidic protein (GFAP)-positive 
astrocytes, which may provide neurotrophic support via secretion of other NTFs, such as 
GDNF as was shown by Tian et al. (2007). Thirdly, VEGF-A may directly influence the DAergic 
neurons via its receptors. However, Yasuhara et al. (2004) did not observe VEGFR-1 or VEGFR-
2 immunoreactivity on DAergic neurons, but neuropilins were present.  
Falk et al. (2009, 2011) have studied the neuroprotective potential of VEGF-B against rotenone 
toxicity in cultured rat midbrain cells and 6-OHDA -induced neurodegeneration in rats. 
Rotenone,  like  6-OHDA,  as  an  inhibitor  of  complex  I  of  the  mitochondrial  respiratory  chain  
also causes an increase in reactive oxygen species which leads to apoptosis in affected cells (Li 
et al., 2003). VEGF-B -expression is upregulated by rotenone treatment in the midbrain cell 
cultures, and exogenously applied VEGF-B protects the cells against the toxin. In the in vivo -
model, amphetamine-induced rotations were significantly reduced in VEGF-B -treated 
animals, and the survival of nigrostriatal neurons was slightly increased. These studies, 
however, did not provide any mechanistic data. VEGF-B acts on VEGFR-1, which could lead to 
activation of astroglia and thus provide indirect neurotrophic support via increased expression 
of other trophic factors, as suggested for VEGF-A. However, Poesen et al. (2008) did not find 
significant astrogliosis after intracerebroventricular administration of VEGF-B, and therefore it 
still  remains  to  be  elucidated,  whether  glial  responses  might  mediate  at  least  some  of  the  
effects of VEGF-B. VEGFR-1 may also mediate direct positive effects on neuronal survival, 
although there is no definite evidence of the presence of the receptor on DAergic neurons. 
Another possible mediator is NRP1, but thus far there are no reports describing its role in the 
neuronal effects of VEGF-B. Finally, worth a mention is that VEGF-B, unlike VEGF-A, does not 
cause significant neovascularization, or vascular leakage when administered into the brain 









2.3.5 Effects of other selected NTFs in the 6-OHDA –models of PD 
Table  9  summarizes  a  list  of  selected  growth  factors  or  molecules  associated  with  neural  
functions,  that have shown therapeutic potential  in the 6-OHDA model of  PD. The list  is  by 
far  not  conclusive  and  could  be  made  much longer  if  all  single  reports  were  to  be  collected.  
However,  these  examples  show  that  a  variety  of  growth  factors  that  are  often  implicated  in  
other physiological events can have positive effects on the DAergic system. 
Fibroblast growth factor-2 (FGF-2) belongs to a large family of FGFs that have important 
functions during development, such as regulation of cell migration and formation of tissues 
and limbs (Grothe and Timmer, 2007). They are also implicated in neural development, 
protection and regeneration both in the central and peripheral nervous system. FGF2 and its 
tyrosine kinase receptors are expressed by the nigrostriatal DAergic neurons, and FGF2 is 
retrogradely transported in this pathway. Therefore, it is not surprising that exogenously 
applied FGF2 can protect midbrain DAergic neurons in vitro and in vivo. Additionally, 6-
OHDA has been given to FGF2 –deficient and FGF2 –overexpressing mice (Timmer et al., 
2007). Nigral TH-positive cells of the knock-out mice were moderately more prone to die after 
6-OHDA insult, whereas the neurons of FGF2 –overexpressing mice were more resistant. 
Growth/differentiation factor 5 (GDF5) is a member of the TGF  –superfamily (reviewed by 
Sullivan and O'Keeffe, 2005). It is mostly implicated in skeletal and tendon development and 
joint morphogenesis for example through accelerating chondrocyte proliferation and 
differentiation. GDF5 and its receptors are expressed both in developing and adult rat brain. It 
has  been  shown that  GDF5  can  protect  embryonic  DAergic  neurons  and  induce  TH-positive  
phenotype in vitro. Although it is not clear how the effects of GDF5 on neuronal survival and 
behavioural deficits are mediated, it has been hypothesized that the effect falls directly upon 
neurons and at least is not mediated via astrocytes.  
HB-GAM, also known as pleiotrophin has diverse roles in and outside the nervous system 
(Deuel et al., 2002). It is involved in the differentiation of glial cells, neurite outgrowth, 
synaptic plasticity, angiogenesis and mitogenesis of several cell types in the periphery. It 
signals through receptor tyrosine phosphatase  as well as syndecan-3, which both are 
expressed by SN DAergic neurons (Marchionini et al., 2007, Ferrario et al., 2008, Taravini et 
al., 2011). Interestingly, the latter has been shown to be a receptor for GFLs as well (Bespalov et 
al., 2011). HB-GAM has also been implicated in the development of DAergic neurons, and there 
is a slight increase in HB-GAM –expressing cells in the SN of PD patients (Marchionini et al., 
2007). In vitro,  HB-GAM  can  increase  the  survival  of  TH-positive  primary  neurons, and 
potentiate the effects of GDNF in the same experimental system (Hida et al., 2003). All these 
findings suggest that HB-GAM may have beneficial effects in preclinical models of PD. So far, 
the most successful attempts have been to deliver HB-GAM via viral vectors for sustained 
expression (Taravini et al., 2011, Gombash et al., 2012). Nigral TH-positive neurons were 
protected both in the neuroprotection and neurorestoration paradigms. Behavioural measures 
were improved in the neuroprotection experiments by Gombash et al. (2012) but only when a 
less substantial partial lesion was employed. Unfortunately, striatal TH-immunoreactivity was 
not measured in that experiment, so it is not known, whether reduced paw use asymmetry in 
the cylinder test was related to improvements in DAergic innervation of the striatum.  




EPO  is  a  hormone  regulating  the  production  of  red  blood  cells  in  the  bone  marrow,  and  is  
clinically used in the treatment of anaemia. EPO and its receptor are also found in neurons 
and glial  cells,  and it  seems to have a role in neuronal development and recovery from brain 
injury, such as ischaemia (Sanchez et al., 2009, Jerndal et al., 2010). It was shown that EPO can 
protect DAergic MN9D neurons against 6-OHDA toxicity in vitro by activating the PI3K/Akt –
pathway, a common signalling cascade for NTFs (Signore et al., 2006). In the 6-OHDA -model, 
EPO is active only when given into the brain, not systemically (Xue et al., 2007). Surprisingly, 
intrastriatal AAV-EPO significantly elevates the amount of red blood cells in rats, which raises 
concern  about  the  safety  of  AAV-EPO  (Xue  et  al.,  2010).  It  was  proposed  that  the  use  of  a  
mutated EPO without hematopoietic effects could be a solution to avoid serious side effects 
related to excess production of red blood cells, such as thrombosis.  
IGF1  is  a  polypeptide  mediating  the  effects  of  the  growth  hormone,  and  it  has  growth-
promoting effects in various tissues through regulation of cell growth and development. Both 
IGF1  and  its  receptor  are  abundantly  expressed  in  the  brain  (Bondy  and  Cheng,  2004).  It  is  
known that IGF1 can activate PI3K/Akt –signalling in the brain. Since the same signalling 
cascade is involved in neuronal protection, it is one possible candidate in mediating such 
effects of IGF1 as well. In the 6-OHDA –model, it was confirmed that the positive effects are 
mediated specifically by IGF –signalling, as the effects could be blocked with an IGF-receptor 
antagonist (Quesada and Micevych, 2004). A naturally occurring tripeptide, GPE (glycine-
proline-glutamate), cleaved from the N-terminal of IGF1 exists. It can also prevent DAergic 
neurodegeneration and attenuate behavioural deficits in the 6-OHDA -model (Guan et al., 
2000, Krishnamurthi et al., 2004). It is yet unknown how these effects are mediated, since the 
tripeptide does not activate the IGF1 receptor.  
In  conclusion,  there  is  vast  group  of  molecules  that  primarily  affect  other  processes  in  the  
body, but can be considered as NTFs for the midbrain DAergic neurons. Firstly, this is 
indicative of a complex regulation and perhaps a plethora of compensatory mechanisms 
involved in the development, maintenance and protection of DAergic neurons under normal 
and physiological conditions. Secondly, although it is not always clear how these molecules 
induce their protective effects, their existence may stimulate new ideas to develop novel 
therapies for neurodegenerative brain diseases. In addition, they could be useful as 
conjunction therapy with other NTFs to offer neurotrophic support via different mechanisms 











Table 9. Neuroprotective and neurorestorative effects of selected growth factors in the 
6-OHDA  –rat  model  of  PD.  Table  includes  summaries  of  behavioural  changes,  protection  of  
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CT bias 0 
n.m. SN  
STR 0 
 
AAV=adeno-associated virus, AMPH= amphetamine-induced rotational behaviour, APO= apomorphine 
–induced rotational behaviour, CT= cylinder, EPO= erythropoietin, GDF5= growth/differentiation factor 
5, ICV= intracerebroventriculartly, IGF= insulin-like growth factor, i.p.= intraperitoneally, MFB= medial 
forebrain bundle, NPC= neural progenitor cell, SN=substantia nigra, STR=striatum, SVZ= 
subverntricular zone. Responses of treated animals vs. lesion control animals: 0=no change, = 
increased, =decreased n.m.= not measured. 




2.3.6 General remarks regarding NTF therapy for PD 
Because  of  the  ability  of  NTFs  to  promote  the  survival,  phenotype  and  functionality  of  
neurons, their therapeutic potential to treat neurodegenerative diseases of the brain has been 
under vigorous research. This literature review has covered a portion of growth factors 
affecting the DAergic neurons, and described only the outcomes from the 6-OHDA rodent 
models. If results from other toxin models and the information regarding the development 
and maintenance of DAergic neurons of the brain were included, the evidence of the potential 
of various growth factors would be perhaps even more compelling. Still, although many NTFs 
have been very effective in preclinical models, translation to clinical level remains challenging. 
This  may  be  due  to  several  factors,  and  one  must  always  keep  in  mind  the  limitations  of  
preclinical models. None of the PD models can fully model all the aspects of the disease, and 
quite often the experimental animals are a) of reasonably young age, b) typically either only 
male or female and c) from few litters. Also, when assessing the therapeutic potential of a 
molecule, it is important to assess behavioural read-outs.  
It is a matter of endless discussion, which tests are best suited to give reliable information 
about  the  functional  benefits.  Drug-induced  rotation  is  one  of  the  most  common  ways  to  
assess the DAergic imbalance between hemispheres in unilaterally 6-OHDA –lesioned 
rodents. However, some may argue that this experiment does not represent a natural state of 
the animal, and is a rather robust measure. Therefore, drug-free asymmetry tests seem to be 
gaining popularity as they measure the spontaneous behaviour as well as finer motor 
functions of the animal. Also, NTFs often induce behavioural recovery, typically with 
increased survival of nigral TH-positive neurons but without significant elevations in striatal 
DA content or TH-immunoreactivity when compared to vehicle –treated animals (see above). 
These biochemical measures, however, are not descriptive of the functionality of DAergic 
neurons  –such  as  quanta  of  DA  released,  firing  pattern,  rate  of  DA  reuptake-,  although  
calculation of metabolite/DA –ratios may reveal changes in DA turnover. Also, it is possible 
that even a small increase in striatal DA is enough to alleviate behavioural deficits that may 
manifest only after a certain threshold level of DA-depletion has been reached. Therefore, 
small differences in DA levels that are not statistically significant may still be of functional 
importance. Finally, it is also important not to limit the screening of neurotrophic effects to 
one preclinical model. GDNF, for example, is well known to have potent neurotrophic effects 
in toxin-based models of PD, but is ineffective in rat models based on viral expression of WT 
or A30P-aSyn (Lo Bianco et al., 2004, Decressac et al., 2011).  
Until  today,  only  GDNF  and  NRTN  have  been  clinically  tested  in  PD  patients.  Of  the  four  
clinical trials with GDNF, there was a positive outcome in two (Gill et al., 2003, Patel et al., 
2005, Slevin et al., 2005, Patel et al., 2010), whereas in two studies no improvements were seen 
(Nutt et al., 2003, Lang et al., 2006). These controversial results have been suggested to be due 
to,  in  addition  to  the  open  nature  of  the  studies,  poor  diffusion  of  GDNF  in  the  brain,  
differences in the doses, administration site (ICV in Nutt et al. 2003, intraputaminal in the 
other studies), injection equipment (multiport catheter in Slevin et al. 2005 vs. uniport 
catheter in others) and delivery mode (pulsatile or convection-enhanced in Slevin et  al.  2005 
vs. simple infusion in others) (Salvatore et al., 2006, Aron and Klein, 2011). Also, safety issues 




arose during the trials. Some patients developed antibodies against GDNF, and cerebellar 
lesions were observed in a study on monkeys (Lang et al., 2006, Hovland et al., 2007). Because 
of these reasons and the unsettled clinical efficacy, human trials with GDNF have been 
discontinued. Of note,  there is  no compelling evidence so far linking PD and altered GDNF-
signalling. Genetic variations in the gene coding for GDNF or RET are not associated with PD 
(Wartiovaara et al., 1998, Lucking et al., 2010). The expression of nigral GDNF protein in PD 
patients is either reduced or not changed when compared to control patients (Siegel and 
Chauhan, 2000, Chauhan et al., 2001, Mogi et al., 2001), but a modest increase in GDNF mRNA 
in the putamen of PD patients has been reported, which may reflect a compensatory reaction 
to the ongoing DAergic degeneration (Backman et al., 2006). 
NRTN has been delivered intraputaminally to PD patients via an AAV –vector, CERE-120. It 
was reported that the treatment is well tolerated by the patients and there seemed to be a 
slight improvement in their symptoms (Marks et al., 2008). The improvements remained 
modest also in a later phase II trial, but this has still encouraged further studies in which both 
the putamen and the SN will be targeted (Marks et al., 2010). 
Collectively, these clinical trials represent well some of the challenges related to potential NTF 
therapy  in  PD.  What  has  been  learned  is  that  the  method  of  delivery,  as  well  as  the  site  of  
administration  both  need  to  be  carefully  planned.  Challenges  arise  partially  from  the  
characteristics of the disease itself, as it is a progressive neurodegenerative illness and 
neuronal death is already rather advanced at the moment of diagnosis. Also, the DAergic 
neuronal  death  is  still  rather  poorly  understood,  and  it  is  not  completely  clear  whether  the  
degeneration affects first the axons or the cell bodies (Cheng et al., 2010). Thus, while there is 
a  great  need  for  restorative  therapy,  it  is  equally  important  to  aim  for  earlier  diagnosis  and  
gain further understanding of the mechanisms of neuronal death in PD. 
 




3.  Aims of the study 
 
GDNF still remains as one of the most potent NTFs for DAergic neurons, and therefore more 
effort is needed to study its characteristics and to evaluate its clinical potential further. The 
discovery of new NTFs for DA neurons could lead to new ideas in developing therapeutic 
interventions. Furthermore, genetically modified mice with changes in the signalling of a NTF 
or proper function of  DA may provide a powerful  tool  to dissect the mechanisms of  how the 
protein  in  question  acts  on  the  neurons.  PD  is  a  complex  disorder  with  various  underlying  
factors and their interactions. Mice carrying mutated genes associated with PD may open new 
ways of understanding the pathogenesis and treatment of the disease. 
 
In this context, the specific aims of the study were: 
 
1) To compare the efficacies of GDNF, a N-terminally truncated non-heparin-binding 
variant  ( 38N-GDNF)  and  a  combination  of  GDNF  and  HB-GAM  in  the  unilateral  
6-OHDA rat model of  PD,  and to study if  the diffusion pattern of  GDNF is  changed 
with the amino acid sequence truncation (Study I). 
 
2) To examine the neuroprotective and neurorestorative potential of VEGF-C in the 
unilateral 6-OHDA rat model of PD (Study II, neurorestoration unpublished) 
 
3) To characterize the response of two genetically modified mouse strains to 
intrastriatally administered 6-OHDA. Both genetic modifications are strongly bound 
to DAergic function: a) MEN2B knock-in mice with constitutively active RET receptor 
tyrosine kinase, which mediates the effects of GDNF (Study III) and b) A30P-mutated 







4. Experimental procedures 
 
4.1 Animals 
Wistar male rats weighing ~250 g at the start of each experiment were supplied by Harlan, The 
Netherlands or the Laboratory Animal Centre of University of Helsinki, Finland. The rats were 
housed  in  groups  of  2-4,  except  following  any  surgical  procedure,  after  which  they  were  
housed singly over night before regrouping.  
MEN2B (multiple endocrine neoplasia type 2B) knock-in mice and their WT littermates, aged 
8-14 weeks, (Smith-Hicks et al., 2000) were bred and supplied by the Laboratory Animal 
Centre of University of Helsinki, Finland. Transgenic mPrPh(A30P)asyn mice expressing the 
human A30P-aSyn and WT mice (6-17 months old, Yavich et al., 2004) were bred and supplied 
by the National Laboratory Animal Centre of Finland, University of Eastern Finland. The mice 
were  housed  in  groups  of  2-8  until  surgical  procedures,  after  which  they  were  housed  singly  
until the end of all experiments. 
All animals had free access to rodent chow and water, and they were maintained under 12/12 h 
light/dark cycle at a convenient temperature of +20-22 ºC. The experimental procedures were 
approved by the Committee for Animal Experiments at the University of Helsinki, Finland, or 
the National Animal Experiment Board in Finland. 
 
4.2 Drugs and treatments 
6-OHDA (Sigma, St Louis, MO, USA) was dissolved in 0.9% NaCl solution containing 0.02% 
ascorbic acid as an antioxidant, and stereotaxically injected into the brains of mice and rats as 
described in the original publications.  GDNF (Amgen Inc., Thousand Oaks, CA, USA) was 
diluted with 10 mM citric acid in 0.9% NaCl, 38N-GDNF as well as insect cell –derived GDNF 
and VEGF-C were produced at the University of Helsinki (Joukov et al., 1996) and diluted with 
phosphate-buffered saline (PBS). Stereotaxic injection of NTFs is also described in original 
publications  I  and  II.  D-amphetamine  (2.5  mg/kg  intraperitoneally,  produced  by  Faculty  of  
Pharmacy, University of Helsinki, Finland) and tramadol (1 mg/ml/kg subcutaneously, Orion 
Pharma,  Espoo,  Finland)  were  dissolved  in  0,9%  NaCl.  Desipramine  (25  mg/10  ml/kg  
intraperitoneally, Sigma, St Louis, MO, USA) and buprenorphine (0.1 mg/10ml/kg 
subcutaneously, RB Pharmaceuticals, Slough, UK) were dissolved in sterile water. 
 
4.3 Stereotaxic surgery 
The animals were kept under general isoflurane and local lidocaine anaesthesia during the 
surgical procedures. The rats received tramadol (1 mg/kg) and the mice were administered 






4.3.1 Injections of NTFs  
In  study  I,  a  23  G  guide  cannula  was  inserted  3  mm above  the  intended  injection  site  in  the  
striatum (A/P 0.0; M/L  3.5; D/V  5.0) and fixed on the rat skull with dental cement, 18 hours 
before the 6-OHDA –infusion. HB-GAM or PBS was injected at 0.5 l/min via the cannula, 
using a 30G needle attached to a thin polyethylene tube connected to a glass syringe, which 
was  run  by  a  microinfusion  pump.  12  h  later  GDNF  or  38N-GDNF  was  similarly  injected  
through the guide cannula. 6-OHDA was infused 6 h after the administration of GDNF. 
In studies I, II, and VEGF-C –neurorestoration experiments, GDNF, 38N-GDNF and VEGF-C 
were  injected  into  the  striatum,  A/P  +1.0;  M/L  -3.0;  D/V  -5.0,  using  a  10  µl  Hamilton  
microsyringe run by a stereotaxic injector at 1 l/min (Stoelting Co., Wood Dale, IL, USA). The 
NTFs were injected 6 h before 6-OHDA in the neuroprotection studies, but in the 
VEGF-C -neurorestoration study the injections were made 4 weeks after 6-OHDA. 
In  studies  I  and  II,  some  animals  received  only  NTFs  without  lesioning  procedure  to  study  
their diffusion pattern or effects on the intact brain. More detailed information and the 
dosages can be found in the original papers related to the studies. 
4.3.2 6-OHDA –injections 
Only in study I, 6-OHDA was infused simultaneously to four coordinates in the rat striatum 
with a custom-made cannula. Four 29-gauge needles were fixed together with dental cement, 
and each needle was separately connected via a thin polyethylene tube to a glass syringe run 
by  a  microinfusion  pump  to  deliver  four  7  µg/3.5  µl  deposits  of  6-OHDA  at  0.5  l/min.  The  
needles  in  the  block  were  placed  so  that  the  coordinates  for  the  infusions  were  A/P  
+1.3/+0.4 /-0.4/-1.3; M/L -2.6/-3.2/-4.2/-4.5; D/V -5.0.  
In  all  four  studies  6-OHDA was  injected  at  1  l/min  using  a  10  µl  Hamilton  microsyringe.  In  
studies I-II on rats, a dose of 16 µg /4 µl was injected into the striatum using the same 
coordinates as for the NTFs (A/P +1.0; M/L -3.0; D/V -5.0). In addition, the same coordinates 
and  dosage  was  used  also  in  VEGF-C  -neurorestoration  study  with  two  types  of  lesions;  the  
second lesion type was a two-deposit lesion of 2x10 µg in A/P +1.6/-0.4; M/L -2.2/-4.0;D/V -5.0. 
In studies III-IV on mice 0.33-5 µg / 2 µl of 6-OHDA was administered into the striatum, A/P 
+0.7; M/L +1.8; D/V -2.7. 
 
4.4 Behavioural methods 
4.4.1 Rotational behaviour 
A common method to evaluate the function of the nigrostriatal pathway in unilaterally 
6-OHDA –lesioned rodents is to measure rotational behaviour, which manifests after 
administering a DA-releasing or DA-mimicking drug (Ungerstedt and Arbuthnott, 1970). We 
evaluated the efficacy of NTF treatments and the successfulness of 6-OHDA -lesioning by 
measuring D-amphetamine –induced rotational behaviour in rats. The rats were fitted with a 
harness and allowed to habituate for 10-15 min in the rotation bowls (Coulbourn Instruments 





injection of 2.5 mg/ml/kg D-amphetamine. Full ipsilateral and contralateral rotations were 
recorded for 120 min in 5 min blocks, and the data were expressed as net ipsilateral rotations 
(ipsilateral minus contralateral rotations). In study I, rotational behaviour was measured 2, 3, 7 
and  8  weeks  post  lesioning,  and  in  study  II  2,  4,  6  and  8  weeks  post  lesioning.  In  
VEGF-C -neurorestoration experiments, rotational behaviour was first measured 3 weeks post 
lesioning to divide animals into groups of similar average rotational values. Thereafter, 
rotational behaviour was measured 6, 8, 10, 12 and 14 weeks post lesioning. 
D-amphetamine –induced rotations were also measured in mice to assess the sensitivity of 
MEN2B and mPrPh(A30P)asyn mice to 6-OHDA on behavioural level. The mice were fitted 
with plastic collars on the previous day, and on the day of the experiment they were allowed to 
habituate in the rotation bowls for 10-15 min before an injection of D-amphetamine (2.5 mg/10 
ml/kg, i.p.). Full ipsilateral and contralateral rotations were recorded for 90 min, and the data 
were expressed as net ipsilateral rotations (ipsilateral minus contralateral rotations). The 
experiment was done at 3 weeks post lesion in MEN2B mice, and at 2 and 4 weeks post lesion 
in A30P –mice. 
4.4.2 Stride length 
Measurement  of  stride  length  is  a  simple  way  to  study  nigrostriatal  dysfunction  in  mice  
(Fernagut et al., 2002). This method was employed to study the basal motor differences as well 
as the effects of the unilateral 6-OHDA-lesion in mPrPh(A30P)asyn mice. Baseline values were 
measured one week before 6-OHDA, and the effect of lesioning was studied at 3 weeks after 6-
OHDA.  The  average  of  the  longest  three  steps  was  used  as  the  representative  value  for  each  
mouse. 
4.4.3 Locomotor activity 
24 h spontaneous locomotor activity of aged 13.5-17 month-old mPrPh(A30P)asyn mice was 
measured after letting the mice to acclimatize to the conditions in the experiment room for a 
minimum of 3 days. At the start of the lights-on period in the morning, the mice were placed 
in transparent cage inserts (25 cm × 25 cm × 15 cm, with food pellets and a water burette) in 
the activity monitor (MedAssociates, St. Albans, GA, USA). The measurement was started 
immediately to record also the explorative behaviour in a new environment, and the data was 
collected at 15 min intervals. 
D-Amphetamine –induced locomotor activity was measured in 6-month-old mPrPh(A30P)asyn 
mice before 6-OHDA lesioning and rotational experiments to find out if the genotypes had a 
basal  difference in response to D-amphetamine (1  mg/kg or 2.5 mg/kg i.p.).  All  mice used in 
the experiment received both doses with 7 days in between the treatments. The mice were 
allowed  to  explore  the  cages  (described  above,  but  without  food  and  water)  for  10-15  min  
before the actual experiment started. Locomotor activity was recorded for 3 h , data collection 








4.5 Immunohistochemistry and quantification of immunoreactivity 
4.5.1 Tissue preparation 
In all studies with rats, the animals were terminally anaesthetized with pentobarbital (100 
mg/kg), and perfused transcardially with PBS followed by ice-cold 4% paraformaldehyde (PFA, 
in PB, pH 7.2-7.4). The brains were post-fixed in 4% PFA over night in room temperature, and 
then  switched  into  20%  sucrose  in  PB  for  cryoprotection,  and  kept  at  +4°C  until  they  sank.  
The brains were kept deep-frozen at -84°C  until  coronal  sections  (40  µm)  were  cut  on  a  
cryomicrotome. The sections were collected in series of six, and kept free-floating in 
cryoprotectant buffer containing glycerol and ethylene glycol.  
MEN2B mice and mPrPh(A30P)asyn mice were deeply anaesthetized with pentobarbital as 
above, and quickly perfused transcardially with ice cold PBS. Their brains were removed from 
the  skull  and  placed  on  an  ice-cooled  brain  matrix  to  obtain  a  3  mm  slice  containing  both  
striata  which  were  punched  with  a  2  mm  tool.  Alternatively,  the  brain  was  cut  at  the  level  
where the anterior commissure crosses the brain section, and the striata were dissected out 
using forceps. The samples were immediately frozen on dry ice for later high-performance 
liquid chromatography (HPLC) -analysis. The remaining block containing substantia nigra 
was immersion –fixed in 4% PFA over night and thereafter processed for TH-
immunohistochemistry as described above. Some mPrPh(A30P)asyn mice were perfused with 
PFA after PBS to obtain striatal sections for immunohistochemistry as described above for 
rats. 
4.5.2 TH-immunohistochemistry 
TH-immunostaining was performed in all studies. The free-floating sections were rinsed to 
remove cryoprotectant buffer and quenched for 5 min with 3% hydrogen peroxide + 10% 
methanol. The sections were kept for 1 h in 2% normal serum (normal horse serum for rat 
tissues, normal goat serum for mouse tissues, Vector laboratories, Burlingame, CA, USA) to 
reduce non-specific staining. Primary antibody (rat tissue: mouse monoclonal anti-TH 
MAB318, mouse tissue: rabbit polyclonal anti-TH AB152, both from Millipore/Chemicon, 
Temecula, CA, USA) was diluted 1:2000 and the sections were incubated over night. Thereafter 
the sections were incubated with a 1:250 diluted biotinylated secondary antibody (rat tissue: 
horse  anti-mouse  BA2001,  mouse  tissue:  goat  anti-rabbit  BA1000,  both  from  Vector  
Laboratories, Burlingame, CA, USA), which was combined with a standard avidin-biotin 
complex (ABC)  -procedure (Vectastain standard kit, Vector Laboratories, Burlingame, CA, 
USA) to enhance the signal. The staining was visualized with 3,3-diaminobenzidine (DAB, 
Sigma, St. Louis, MO, USA). All incubations were done in room temperature on a sample 
stirrer. The same protocol was modified for a number of other immunohistochemical 
procedures described below. 
Quantification of TH-positive cells was done using the Stereo Investigator software (MBF 
BioScience, Williston, VT, USA). Three or four (for rats or mice, respectively) TH-
immunostained sections around the medial terminal nucleus of the accessory optic tract were 
chosen, and the cells were counted according to optical disector rules. SNpc was contoured at 
4× magnification,  and the cells  counted with optical  fractionator -application using a 60× oil  





with an Optronics digital camera (Goleta, CA, USA). Counting frames of 60×60 m with 
optical disector height at 20 m were placed in a 125×125 m grid for rat sections and a 80x100 
m grid for mouse sections and cast randomly over the SNpc. The counting was set to yield a 
coefficient of error (CE Scheffer) under 0.15, based on all three sections of the intact 
hemisphere. The program estimated the total number of cells in the block of the SNpc defined 
by these three representative sections, which was used for final data handling. 
Densitometric analysis of TH staining in the striatum was performed on pictures of three 
consecutive striatal sections, obtained with either the Stereo Investigator software and 
equipment (described above) or a stereomicroscope (Nikon, Japan) fitted with a DS-Fi1 camera 
head  and  DS-L2  camera  controlling  unit  (Nikon,  Japan).  Images  were  converted  to  grayscale  
and inverted, and the measurements done using Image Pro Plus program (vs. 3.0.1., Media 
Cybernetics, Bethesda, MD, USA). A line was created across the striatum to measure the 
optical density along the line tool. The effect of background staining was corrected by 
obtaining correction values from the corpus callosum of each section and subtracting those 
values from the striatal OD values. The optical density of the lesioned side was expressed as a 
percentage of the intact side. 
4.5.3 aSyn -immunohistochemistry  
Detection of aSyn was performed as described in (Myöhänen et al., 2008) with slight 
modifications. In short, sections were quenched in 10% methanol and 3% H2O2 in PBS (pH 7.4) 
for 10 min, and non-specific binding was blocked with 10% normal donkey serum in PBS (#S30, 
Millipore, Temencula, CA, USA). The sections were incubated overnight at room temperature 
with the primary antibody against aSyn (1:500 with 1% serum; AB6162, AbCam, Cambridge, 
UK). The next day the sections were incubated for 2 h with donkey anti-sheep HRP conjugated 
secondary antibody (1:500 in 1% NDS in PBS; AB6900, AbCam). Staining was visualized with 
3,3'-diaminobenzidine. 
The optical density of aSyn –immunoreactivity was measured from striatum, SN and motor 
cortex as described above for TH-immunoreactivity. 
4.5.4 DAT –immunohistochemistry  
DAT-immunostaining was performed according to the procedures described for TH-
immunohistochemistry with some exceptions. Normal rabbit serum was used for blocking, 
and a monoclonal rat anti-DAT primary antibody (1:2000, MAB369, Millipore), and 
biotinylated rabbit anti-rat secondary antibody (1:250, BA4000, Vector laboratories) were 
combined. The signal was enhanced with the ABC –procedure and visualized with DAB. The 
optical density of DAT –immunoreactivity in the striata was measured as described above for 
TH-immunoreactivity. 
4.5.5 EBA –immunohistochemistry  
Blood vessels with intact BBB in brains injected with VEGF-C were immunostained using a 
mouse monoclonal antibody raised against rat endothelial barrier antigen (EBA) (anti-
SMI-71R, 1:2000, Covance, Emeryville, CA, USA) in combination with a biotinylated horse anti-
mouse secondary antibody BA2001 (1:500, Vector Laboratories, Burlingame, CA, USA). ABC 





Representative pictures of three consecutive striatal sections were taken for analysis using 
Stereo Investigator software, and the amount of immunoreactive objects was estimated using  
Image Pro Plus -program. A circular area of preset size was placed above the injection site and 
the program counted blood vessels of preset intensity and size (larger than 300 U) inside the 
area. 
4.5.6 GDNF-immunohistochemistry  
Injected GDNF –protein was visualized from the rat striata using a protocol described by 
(Kirik et al., 2000b). In short, the sections were quenched in 3% hydrogen peroxide + 10% 
methanol for 10 min, blocked in 5% normal horse serum for 1 h and incubated in the primary 
antibody (1:3000, goat polyclonal anti-GDNF, R&D systems, Minneapolis, MN, USA) over 
night. Biotinylated secondary antibody (1:200, horse anti-goat BA9500, Vector Laboratories, 
Burlingame, CA, USA) was added in 2% normal horse serum, and the sections were incubated 
for 2 h before ABC –enhancement and DAB –visualization.  
The volume of GDNF-immunoreactivity was estimated using the Cavalieri estimator –probe in 
Stereo Investigator. The immunostained area was contoured at 4x magnification, and markers 
were  cast  over  in  a  750x750  µm  grid.  All  markers  falling  inside  the  contoured  area  were  
counted. 
4.5.7 GFAP –immunohistochemistry  
VEGF-C –induced astrogliosis was studied by staining GFAP-immunoreactive cells from 
striatal sections around the protein injection site. A polyclonal antibody AB5804 raised in 
rabbit (1:1500, Millipore, Temecula, CA, USA) and a biotinylated goat anti-rabbit secondary 
antibody BA1000 (1:500, Vector Laboratories, Burlingame, CA, USA) in 1% normal goat serum 
were used and signal was enhanced with ABC procedure before DAB reaction.  
The number of GFAP-positive cells was estimated using Stereo Investigator as described above 
using three striatal sections around the injection site, placing approximately 20 counting 
frames (100×100 m, optical  disector height 20 m, in a 650×650 m grid) per striatum. The 
estimated  total  number  of  cells  by  the  program was  used  as  a  parameter  for  calculating  the  
results. 
4.5.8 Iba1a –immunohistochemistry  
To visualize microglia in striatal sections from rat brains treated with VEGF-C, a polyclonal 
antibody against the microglial marker, ionized calcium binding adaptor molecule (1Iba1) 
(1:1000, raised in rabbit, Wako Pure Chemical Industries, Tokyo, Japan) and a biotinylated goat 
anti-rabbit secondary antibody BA1000 (1:500, Vector Laboratories, Burlingame, CA, USA) 
were used in combination with ABC procedure before DAB reaction.  
Iba1 -positive objects were counted using Stereo Investigator with the same settings as 
described for GFAP-reactive cells. Resting and activated microglia were roughly separated by 
their  morphology  and  counted  using  different  markers  to  make  an  estimate  of  the  total  
number of microglia and the number of activated microglia. A microglial cell was considered 






4.6 Analysis of monoamines from brain tissue 
The concentrations of DA and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and 
homovanillic acid (HVA), as well as 5-hydroxytryptamine (5-HT) and its metabolite 5-
hydroxyindoleacetic acid (5-HIAA) were measured from striatal tissue samples obtained from 
MEN2B and mPrPh(A30P)asyn mice as described in the original publications III and IV. We 
followed the original method described in detail in (Airavaara et al., 2006), with minor 
modifications of the mobile phase when needed.  
 
4.7 Western blotting of MAPK/ERK 
The ability of VEGF-C to activate MAPK/ERK –pathway in the rat brain was studied with 
western blot. Striatal tissue samples, obtained 1 or 8 h after an injection of 20 g VEGF-C into 
the  striatum,  were  homogenized  in  buffer  containing  0.3  M  sucrose,  10  mM  Hepes  pH  7.4,  
1 mM EDTA, PhosSTOP phosphatase inhibitor and Complete protease inhibitor cocktail 
tablets (both from Roche, Mannheim, Germany) and kept on ice. Protein concentration was 
measured using a BCA kit (Pierce, Rockford, IL, USA). The samples were electrophoresed on 
7.5-10% SDS-PAGE and transferred on nitrocellulose membranes. The membranes were 
incubated with rabbit polyclonal anti-phospho-ERK1/2 1:1000 in 5% milk (#9101, Cell Signaling 
Technology, Beverly, MA, USA) and thereafter with goat anti-rabbit secondary antibody 1:3000 
in 5% milk (#172-1019, Bio-Rad Laboratories, Hercules, CA, USA). The signal was developed 
with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Rockford, 
IL, USA). The membrane was then stripped, washed and incubated with rabbit polyclonal 
anti-ERK1 1:500 in 5% milk (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Treatment with 
secondary antibody and signal development was done as with phospho-ERK1/2. Densitometric 
analysis was performed in AIDA Image Analyzer software (Raytest Isotopenmessgeräte, 
Straubenhardt, Germany), or GeneGnome chemiluminescent detector (Syngene, Synoptics 
LTD, Cambridge, UK) to measure histogram profiles for all bands.  
 
4.8 Statistics 
In  studies  I-II,  the  data  from  rotational  experiments,   TH-cell  counts,  optical  density  of  TH  
staining, and distribution of injected GDNF were analyzed with one-way analysis of variance 
(ANOVA) combined with Tukey’s post hoc –test,  or  Tukey’s  b  –test.  Two-way  ANOVA  was  
used in analysis  of  rotational  behaviour and stride length in mice (study IV),  TH-cell  counts 
(Studies I, III, IV), density of TH- and DAT –immunoreactivity (Study IV) and striatal 
monoamine concentrations (studies III and IV). ANOVA of repeated measures was used for 
analyzing the data from measuring locomotor activity (study IV). Unpaired Student’s t-test 
was used for comparing EBA-, GFAP-, and Iba1a –stainings between control and treatment 
(Study II), and rotational behaviour, TH-cell data, striatal DA content, striatal metabolite/DA 









5.1 Effects of truncation of the amino acid sequence or preadministration 
of  HB-GAM  on  the  diffusion  pattern  and  neuroprotective  efficacy  of  
GDNF (I) 
As shown in Table 10, removal of the first 38 amino acids, containing the sequence responsible 
for high affinity for heparin-like structures, from the structure of GDNF leads to markedly 
increased  diffusion  of  the  NTF  in  the  rat  brain  (P<0.001 38N-GDNF  vs.  both  full  GDNF-
proteins). The effect is apparent immediately after administration. Pretreatment with HB-
GAM 18 h before GDNF –injection did not alter the diffusion pattern significantly (11.0-12.9 
mm3, result from a pilot study and not included in the table).  
 
Table 10. Diffusion volumes of GDNF –variants after intrastriatal injections 
 Diffusion volume, mm3 
GDNF-variant 10 min 6 h 
full GDNF (E. Coli) 7.5±1.2 14.1±1.3 
full GDNF (baculo) 10.0±1.2 15.1±1.0 
38N-GDNF (baculo) 18.2±1.0 *** 25.0±1.4*** 
Average±SEM, n=5-11. *** P<0.001 one-way ANOVA followed by Tukey’s post hoc 
 
Results from the rotational behaviour experiments (Fig. 5 a) show, that GDNF alone seems to 
be most effective in reducing D-amphetamine –induced ipsilateral turning in rats with four-
site lesions. 38N-GDNF  could  also  partially  reverse  the  motoric  bias,  but  not  to  the  same  
extent as full GDNF. The behavioural measures were supported by the analysis of TH-positive 
cells  of  the  SNpc  showing  that  38N-GDNF did not protect the cells as effectively as full 
GDNF (Fig. 5 b). However, when the GDNF –variants were studied employing a considerably 
smaller one-site 6-OHDA lesion, they were equally effective (see details and full sets of results 
in original publication I).  
Pretreatment with HB-GAM 18 h before GDNF inhibited the functional recovery in a 
dose-dependent manner (Fig. 5 c), but did not affect the ability of GDNF to protect the 
DAergic cell bodies in the SNpc (Fig. 5 d). HB-GAM alone did not increase the survival of TH-






Figure 5. Neuroprotective effects of 38N-GDNF and HB-GAM/GDNF –combination 
treatment in the unilateral 6-OHDA rat model of PD.  Rats  were  injected  with  3  or  10  µg  of  
38N-GDNF, 10 µg of GDNF, 17 or 50 µg of HB-GAM, or a combination of HB-GAM and GDNF 6 h 
before 6-OHDA (4x7 µg). a-b) D-amphetamine -induced ipsilateral rotational behaviour 8 weeks post 
lesion;  c-d)  survival  of  TH-positive  cells  in  the  SNpc.  *P<0.05,  **P<0.01,  ***P<0.001  vs.  control;  
#P<0.05, ##P<0.01 vs.3 µg 38N-GDNF  (one-way  ANOVA  and  Tukey’s  post  hoc  test,  except  in  d)  
two-way ANOVA for the effect of GDNF). average+SEM, n=6-13 
 
5.2 Effects of VEGF-C in the unilateral 6-OHDA rat model (II) 
The potential dopaminotrophic effects of VEGF-C were studied both in a neuroprotection 
protocol, in which VEGF-C was administered 6 h before 6-OHDA into the striatum, and in a 
neurorestoration protocol, in which VEGF-C was injected 4 weeks after 6-OHDA lesioning. 
Fig. 6 summarizes the findings from the neuroprotection experiments (for full sets of data, see 
original publication II). We found that a 30-µg dose of VEGF-C can reduce D-amphetamine-
induced rotational behaviour in rats as effectively as 10 µg of GDNF. However, combining the 
two NTFs did not result in additional efficacy (Fig. 6 a). When examining the survival of TH-
positive  cell  bodies  in  the  SNpc,  it  was  quite  apparent  that  VEGF-C  had  only  a  modest  
protective effect in comparison to GDNF. In contrast to the behavioural effect, the 
combination treatment with GDNF and VEGF-C apparently protected the nigral DAergic cells 
more  effectively  than  GDNF  alone  (Fig.  6  b),  although  this  effect  did  not  differ  statistically  
significantly from that of GDNF. The analysis of TH-immunoreactivity in the rat striata 
showed a more robust protective effect of VEGF-C (Fig. 6 c), when compared to its effect on 







Figure 6. Neuroprotective effects of VEGF-C in the unilateral 6-OHDA rat model of PD. a) D-
amphetamine –induced ipsilateral rotational behaviour 4 weeks post lesion in rats treated with 10-30 
µg  VEGF-C  (V),  10  µg  GDNF  (G)  or  their  combination  (V+G,  1o  µg  each)  6  h  before  6-OHDA,  b)  
survival of TH-positive cells in the SNpc, c) optical density of striatal TH-immunoreactivity. *P<0.05 
vs. control (one-way ANOVA and Tukey’s post hoc test or Tukey’s b-test), average+SEM, n=7-17. 
 
After the neuroprotection experiments, the neurorestorative potential of VEGF-C was studied 
in two unilateral 6-OHDA lesions (Table 11). When a smaller, one site lesion (16 µg 6-OHDA) 
was employed, an attenuation in rotational behaviour could be observed in all treatment 
groups (VEGF-C, GDNF and the combination of both), but the rotations were reduced also in 
the control animals over time. None of the effects of NTFs were statistically significant at any 
time  point  or  when  the  AUC  curves  (change  in  number  of  rotations  during  3-14  weeks  post  
lesion) were compared due to high variation in each group. No significant differences were 
observed  between  the  groups  in  the  survival  of  TH-positive  neurons  in  the  SNpc,  or  TH-
immunoreactivity of  the striata.  However,  when comparing the striatal  OD values,  there is  a  
small positive effect of GDNF. 
When a substantially larger lesion (2x10 µg 6-OHDA) was employed, the NTF treatments 
hardly affected the rotational behaviour of the rats (Table 11). Even GDNF failed to effectively 
abolish the motoric bias in such a severe lesion, in which only 17 % of nigral DAergic cell 
bodies could be detected in morphological analysis. Nevertheless, counting of nigral TH-
positive cells revealed a clear positive effect of GDNF on the survival of DAergic cell bodies, 
even though the overall result of the statistical test was not quite significant (P=0.054, one-














 Table 11. Results from VEGF-C neurorestoration studies 
AUC= area under the curve. Average±SEM, n=7-8. n.d. = not determined. P>0.05  in  all  comparisons  
(one-way ANOVA). 
 
5.3 Changes in the intact rat brain after intrastriatal VEGF-C 
administration (II) 
Astroglial and microglial activation as well as BBB disruption was studied by 
immunohistochemistry 3 days after administration of  20 µg of  VEGF-C or vehicle into intact 
rat striatum. There was a marked increase in GFAP –immunoreactive astroglia and Iba1a-
immunoreactive microglia after VEGF-C treatment. The number of activated microglia was 
increased as well. In addition, VEGF-C caused a reduction in EBA-staining, which indicates a 
disruption of the BBB. The results are shown in Table 12. 
 
Table 12. Effect of VEGF-C on numbers of astroglia, microglia, and intact blood vessels 
 Estimated no. of objects x 103 
Biomarker VEGF-C 20 µg vehicle 
GFAP (astroglia) 50±5** 24±3 
Iba1a (microglia), total 208±8** 125±6 
-activated 184±9 ** 50±6 
EBA (BBB) 0.87±0.1 *** 1.4±0.04 




control VEGF-C   10 µg 
GDNF 
10 µg 
VEGF-C  5 µg 
+ GDNF 5 µg 
VEGF-C  10 µg 
+ GDNF 10 µg 
16 µg 6-OHDA      
AUC; rotations 3-14 
weeks post lesion 
3,768±1437 1,835±679 1,822±961 n.d. 2,461±672 
TH+ cells in SNpc  
(% of intact) 
42.1±11.5 51.9±4.8 47.2±7.5 n.d. 44.2±8.7 
TH+ staining in STR 
(% of intact) 
38.4±7.2 39.9±7.0 50.7±2.6 n.d. 41.8±6.3 
2x10 µg 6-OHDA      
AUC; rotations 3-14 
weeks post lesion 
8,005±1,532 6,661±1,518 7,023±1,762 5,883±1,480 6,295±886 
TH+ cells in SNpc  
(% of intact) 
17.0±4.4 26.6±6.9 34.2±4.5 33.0±5.7 38.7±3.9 
TH+ staining in STR 
(% of intact) 





In search of possible signalling pathways for VEGF-C, the activation of MAPK/ERK –pathway 
was examined in intact striatal tissue by western blotting 1 and 8 h after an intrastriatal 
injection  of  the  growth  factor.  At  1  h  post  injection,  there  was  an  increase  of  16±3.7%  
(average±SEM) in the ERK phosphorylation when compared to the vehicle-injected samples 
(P<0.05, one sample t-test). At 8 h post-injection the trend still existed (26±37% increase), but 
there was no statistically significant difference between treated and vehicle –samples. 
 
5.4 Effects of 6-OHDA on the nigrostriatal pathway in MEN2B mice (III) 
When D-amphetamine –induced ipsilateral rotations were measured in MEN2B mice and their 
WT littermates 3 weeks after a unilateral 6-OHDA injection, the homozygous M/M knock-
in -mice rotated notably more, although the effect was quite not statistically significant (Fig. 
7a).  Analysis  of  striatal  DA  concentrations  revealed  a  slightly  greater  loss  of  DA  in  the  WT  
mice,  when the  remaining  amount  of  DA was  expressed  as  percentage  of  the  intact  samples  
(Fig. 7 b). Also, M/M mice had greatly elevated basal DA levels, which is in agreement with 
earlier studies (Mijatovic et al., 2007). Despite the extensive loss of striatal DA in both 
genotypes, quantification of nigral TH-positive cells revealed only minor degeneration in M/M 
mice, and approximately 36% neuronal loss in the WT mice (Fig. 7 c). 
 
Figure 7. Effects of intrastriatally administered 6-OHDA (5 µg) in MEN2B and WT mice. a) D-
amphetamine –induced rotational behaviour 3 weeks post lesion, b) striatal DA concentrations, c) 
survival of DAergic cell bodies in the SNpc. *P<0.05, **P<0.01 (unpaired Student’s t-test). Data 










5.5 Locomotor activity and rotational behaviour in mPrPh(A3oP)asyn 
mice (IV) 
In mPrPh(A30P)asyn transgenic (+/+) mice, there is an age-dependent development of 
spontaneous motor impairments. At the age of 6 months there were no significant differences 
between +/+ mice and their WT littermates in locomotor activity, which was measured for 24 
h  (data  not  shown).  However,  at  the  age  of  14-17  months,  we  found  significant  decreases  in  
locomotor activity at certain time points in A30P +/+ mice, even though the cumulative 
distances did not differ between the genotypes (Table 13). The decreases were especially 
evident  during  normal  high  activity  periods,  such  as  the  start  of  the  12-h  dark  period  or  the  
exploratory phase in the beginning of the experiment. During the activity peak periods, the 
WT mice were actively rearing (vertical movement), which was almost completely absent in 
+/+ mice. 
Since the younger mice did not exhibit any detectable basal motor impairments, they were 
challenged with D-amphetamine (1 mg/kg and 2.5 mg/kg). This experiment revealed, that the 
locomotor response to the lower dose was significantly attenuated in +/+ mice. At the higher 
dose of D-amphetamine, there were no differences in travelled distances between the two 
genotypes. The higher dose was later used for inducing rotational behaviour in 6-OHDA-
lesioned mice, assuming that possible differences in the experiment would not be due to 
different responses to D-amphetamine. 
 
Table 13. Cumulative locomotor activity counts in mPrPh(A30P)asyn mice 
 Genotype 
Measurement WT/WT +/+ 
24 h locomotor activity (aged mice)   
- distance travelled (m) 894±93 870±104 
- vertical counts 2065±200 999±232** 
   
D-AMPH –induced locomotor activity (young mice) 
- distance travelled (m), 1 mg/kg 167±23 84±9*** 
- distance travelled (m),  2.5 mg/kg 518±100 632±121 
Average ±SEM, n=11-12. ** P<0.01, *** P<0.001, unpaired Student’s t-test 
 
Rotational behaviour was measured in 6-OHDA –treated mPrPh(A30P)asyn mice at two and 
four weeks post lesion (Fig. 8 a, b, see next section). We observed that, in general, WT/WT –
mice required a higher dose of 6-OHDA to exhibit a rotational bias in any direction. The 
smallest dose of 6-OHDA (0.33 µg) caused the +/+ -mice to rotate contralaterally in response 
to D-amphetamine, but with higher doses they rotated ipsilaterally, making more rotations in 
120 min than their WT littermates. The differences seen between the genotypes were 
significant at two weeks post lesion (genotype x treatment, P=0.02, two-way ANOVA), and 






Between the rotational tests at 3 weeks post lesioning, the stride lengths of mPrPh(A30P)asyn 
mice were measured. The baseline values, measured four weeks earlier, were not significantly 
different between the genotypes (6.6±0.54 in WT/WT, 6.5±0.71 in +/+ mice). However, we 
observed a slight but significant decline in the stride length in +/+ mice after lesioning 
(6.2±0.95/5.8±0.74/5.9±0.72 for 0.33/1.0/3.0 µg of 6-OHDA, respectively), but not in WT/WT 
mice (6.8±0.45/6.9±0.8/6.5±1.0 for 0.33/1.0/3.0 µg of 6-OHDA, respectively). There was no 
treatment effect of 6-OHDA, but a significant genotype effect was revealed by two-way 
ANOVA (P<0.001).  
 
5.6 Biochemical and neuropathological changes in 6-OHDA –treated and 
aged transgenic mPrP(A3oP)asyn +/+ mice (IV) 
Four  to  seven  days  after  the  last  test  of  rotational  behaviour,  brain  samples  from  6-OHDA-
treated mice were taken for immunohistochemistry and monoamine measurements. We 
immunostained  TH  and  DAT  in  striatal,  and  only  TH  in  midbrain  sections  of  the  mice  to  
evaluate, whether the above mentioned behavioural differences could be explained with 
morphological findings. We saw a clear dose-response of 6-OHDA on the loss of TH-positive 
neurons in the SNpc (Fig. 8 c-e, treatment effect P<0.001, two-way ANOVA), and the loss of 
TH- and DAT-immunoreactivity in the striatum in both genotypes. However, the extent of 
these degenerative changes were similar in +/+ and WT/WT –mice, indicating that the 
sensitivity to 6-OHDA was not increased in +/+ mice. There were no basal differences in DAT-
staining  or  number  of  TH-cells  in  SNpc,  but  we  detected  a  slight  decrease  in  striatal  TH-
immunoreactivity on the intact side (data not shown). 
We studied the 6-OHDA –induced changes in the brain of mPrPh(A30P)asyn mice further by 
HPLC-analysis of DA and its metabolites, as well as 5-HT in the striatum (Fig. 9). Significant 
genotype (P=0.009, two-way ANOVA) and treatment (P<0.001, two-way ANOVA) effects were 
seen in DA concentrations, but without interaction of these factors (Fig. 9 a). An interesting 
phenomenon was seen in 0.33 µg 6-OHDA-lesioned +/+ mice, since their striatal DA content 
was increased with lesioning. DOPAC concentrations were generally higher in +/+ mice (Fig. 
9 b, P=0.007, two-way ANOVA). There were no significant differences in HVA concentrations 
due to high variation. 5-HT –concentrations were generally higher in +/+ mice, but the effect 
of 6-OHDA was similar in both genotypes (Fig 9 d, genotype effect P<0.001, treatment effect 






Figure 8. Effects of different doses of 6-OHDA on rotational behaviour and DAergic markers 
in mPrPh(A30P)asyn mice. a) D-amphetamine –induced (2.5 mg/kg, i.p.) rotational behaviour 2 
weeks  post  lesion;  genotype  x  dose  P=0.02  (two-way  ANOVA);  b)  D-amphetamine  –induced  (2.5  
mg/kg, i.p.) rotational behaviour 4 weeks post lesion; genotype x dose P=0.056 (two-way ANOVA); c) 
Number of TH-positive neurons in the SNpc; d) optical density of TH-immunostaining in the striata; 
e)  optical  density  of  DAT-immunostaining  in  the  striata.  6-OHDA-treatment  effect  in  c,  d  and  e:  
P<0.001 (two-way ANOVA). Data expressed as average+SEM, n=8-1 in a-c; n=3-5 in d, e. 
 
Metabolite/DA ratios were calculated to detect possible changes in DA turnover (Fig. 9 e). 
Significant genotype and lesioning effects, but without interaction, were seen in 
mPrPh(A30P)asyn mice (P=0.016 and P<0.001 respectively, two-way ANOVA) in DOPAC/DA 
ratios.  In  HVA/DA  -ratios,  only  the  6-OHDA-treatment  effect  was  apparent  (P<0.001, two-
way-ANOVA) although in general the concentrations comply with those of DOPAC. 
Finally, we investigated the brain accumulation of aSyn in young and aged mPrPh(A30P)asyn 
mice.  We  found  that  in  all  three  brain  areas  that  we  analyzed,  +/+  mice  had  significantly  
increased aSyn immunoreactivity (Fig. 10). This can be explained by the fact that these mice 
have an inserted A30P –gene, so the total aSyn load is higher. We also saw an age-related 







Fig. 9. Striatal concentrations of DA, DOPAC, HVA and 5-HT, and metabolite/DA ratios in 
mPrPh(A30P)asyn mice after 6-OHDA –lesioning. a-d) Concentrations of each analyte expressed 
as  ng/mg  tissue  weight.  Significant  genotype  (GT)  and  lesion  effects  in  a  and  e,  GT  x  lesion  
interaction in b (two-way ANOVA). e) metabolite/DA –ratios calculated for indices of DA turnover. 
Significant GT and lesion effects in DOPAC/DA and lesion effect in HVA/DA (two-way ANOVA). 
Data expressed as average+SEM, n= 15 in pooled intact samples, n=5 in 6-OHDA –treated samples.  
 
 
Fig. 10. Optical density of aSyn –immunoreactivity in the substantia nigra (SN), striatum 
(STR) and motor cortex (M1 cortex) of mPrPh(A30P)asyn mice. In all investigated brain areas, 
there was a significant genotype effect, and in the STR and M1 cortex also a significant age effect 





Table 14. Summary of findings in mPrPh(A30P)asyn mice 
Measure 
Change in +/+ mice 
in comparison to 
WT/WT mice 
Basal locomotor activity, 24 h 0 
Basal vertical activity, 24 h  
D-amphetamine-induced locomotor 
activity, 1 mg/kg  (2.5 mg/kg)  (0) 
aSyn immunoreactivity of the brain  
Basal DA and DA turnover  
After 6-OHDA –lesioning:  
Stride length  
D-amphetamine –induced rotational 
behaviour  
Loss of DAergic markers in the 
nigro-striatal pathway 0 
Loss of striatal DA, DA turnover 












6.1 Truncation of GDNF increases the diffusion of the protein in vivo (I) 
GDNF has a high affinity for heparin-like structures, which is also made use of in the protein 
purification process (Lin et al., 1993, Lin et al., 1994). This phenomenon may also lie behind 
the observations that GDNF diffuses poorly in the brain. It has even been suggested that 
inadequate diffusion of the protein was one of the pitfalls in the clinical trials. Therefore, it 
was an intriguing idea to test, whether a change in the heparin-binging affinity of GDNF 
would  increase  the  spreading  in  the  brain.  It  was  shown  earlier  that  a  co-infusion  of  GDNF  
and heparin increases the biodistribution of GDNF in the rat striatum, most likely due to 
GDNF  binding  to  heparin  instead  of  heparan  sulphates  in  the  brain,  but  at  that  time  no  
behavioural responses were measured (Hamilton et al., 2001). 
The heparin-binding motifs of GDNF are located within the first 16 amino acids of the 
sequence, discarding of which greatly reduces the affinity of GDNF to heparin without 
affecting its ability to bind GFR 1 (Alfano et al., 2007). Therefore, we hypothesized that the N-
terminally truncated GDNF-variant, 38N-GDNF,  would  diffuse  farther  in  the  brain  in  
comparison to the full protein due to reduced binding to heparan sulphate structures on the 
cell surfaces and in the extracellular matrix of the brain. Indeed, we found that the truncated 
variant has a markedly increased diffusion volume when injected into the rat striatum. The 
effect was evident already immediately after the injection, and persisted at least until 6 h post 
injection. Surprisingly, both our behavioural and morphological data suggest that despite 
being biologically active and stable, 38N-GDNF is not as potent as full GDNF in the 6-OHDA 
rat model of PD. Based on these findings we concluded that the poorer in vivo effect of 38N-
GDNF was due to impaired heparin binding, and not because of loss of activity. 
Our  second  approach  in  trying  to  increase  the  distribution  of  GDNF  was  to  first  inject  HB-
GAM to saturate its heparan sulphate proteoglycan (HSPG) receptor, syndecan-3, and thus 
reduce the binding of GDNF to this receptor. In a pilot study, we did not detect any signs of 
enhanced biodistribution, but later saw an impaired behavioural recovery in comparison to 
animals treated with GDNF alone. Pretreatment with HB-GAM dose-dependently prevented 
the GDNF-induced reduction of ipsilateral rotations, but did not affect the ability of GDNF to 
protect nigral DAergic cells. HB-GAM alone, however, did not have a significant effect on the 
rotational behaviour, and it did not protect the DAergic cell bodies in the SN when compared 
to vehicle control group. As mentioned before, sustained delivery of HB-GAM via viral vectors 
has been a more successful approach, leading to protection of TH-positive cells in the SN and 
TH-positive fibers in the striatum, as well as amelioration of paw use asymmetry depending on 
the experimental setup (Taravini et al., 2011, Gombash et al., 2012).  
Interestingly, Bespalov et al. (2011) have shown that indeed, GDNF binds to syndecan-3 with 
high affinity. They suggested that the interaction between soluble GDNF and syndecan-3 
serves to keep GDNF available for its receptors, whereas the same interaction with 
immobilized GDNF in the extracellular matrix is involved in neurite outgrowth and migration 





syndecan-3 deficient cells/animals are used, or when heparan sulphate chains of the receptor 
are enzymatically cleaved by heparinase III. In this context, it is possible that the pretreatment 
with HB-GAM may interrupt the neuritogenic effects of GDNF as they can both bind 
syndecan-3, and so attenuate the positive behavioural response. Also, this may explain the 
weaker effect of 38N-GDNF in  our  experiments  as  the  protein  is  not  capable  of  binding  to  
syndecan-3. Thus, it would not be kept concentrated near its receptors, which seems to be 
needed to gain adequate response. As we did not measure the optical density of striatal TH-
immunoreactivity in Study I, this putative effect still remains to be confirmed. 
 
6.2 VEGF-C reduces rotational bias in a neuroprotection set-up in the 
6-OHDA rat model (II) 
VEGF-family proteins have consistently been shown to have effects in the central nervous 
system. VEGF-A has been extensively studied, and it is known to directly promote the survival 
of neurons through various mechanisms. Also VEGF-B has been shown to protect a variety of 
neurons,  and  it  is  effective  in  cellular  and  animal  models  of  PD  (Falk  et  al.,  2011).  Neuronal  
effects of VEGF-C, on the other hand, have been fairly little studied. It is required for the 
proliferation of neural progenitors as well as oligodendrocyte precursor cells of the optic 
nerve, and it has been detected in the brains of embryonic, neonatal and adult mice (Le Bras 
et  al.,  2006,  Kranich  et  al.,  2009).  Also,  both  the  VEGF-C  protein  and  its  receptor  VEGFR-3  
were upregulated in the ischaemic rat hippocampus (Shin et al., 2008). After our initial finding 
demonstrating that Vegfc is one of the genes upregulated in N2A –cells after GDNF treatment, 
we hypothesized that VEGF-C has neurotrophic actions against neurodegeneration.  
Before conducting in vivo experiments, we examined the ability of VEGF-C to protect DAergic 
cells in a primary embryonic midbrain culture. We found a modest increase in the survival of 
TH-positive neurons in comparison to the strong effect of GDNF, which was used as a positive 
control (see original publication II for details and figures). In the 6-OHDA rat model of PD 
however, we observed a robust reduction in the rotational behaviour of the rats that were 
treated with VEGF-C 6 h before lesioning.  The effect was even comparable to that of  GDNF, 
albeit with a higher dose. Surprisingly, TH-positive cells of SNpc were not significantly 
protected against 6-OHDA by VEGF-C, but the effect of GDNF was clear. Striatal TH-
immunoreactivity was slightly better preserved with VEGF-C than were nigral DAergic cells, 
but  not  significantly  more  than  in  the  control  group.  Since  it  is  thought  that  the  rotational  
behaviour induced by amphetamine is a measure of imbalance in striatal DA release between 
the two brain hemispheres, it must be taken into account that measuring the number of TH-
positive cells or striatal DAergic fiber density will not reveal any changes in storage, release, or 
metabolism of DA in the surviving neurons, which can contribute to behavioural recovery. On 
the other hand, although the effect of VEGF-C on the survival of TH-neurons was modest and 
statistically non-significant (on average +11 %-points for TH-positive neurons and +19 %-points 
for striatal optical density in comparison to the control group), it may still have a role in the 
robust  reduction  of  the  rotational  behaviour.  The  control  group  had  on  average  a  40  %  
reduction in TH-positive cells and a 60 % reduction in striatal TH-immunoreactivity. These 





by amphetamine (Schwarting and Huston, 1996a). Therefore, even a small 10-20% increase in 
the preservation of DAergic function may notably reduce the turning behaviour of a rat.  
GDNF, as a powerful NTF for DAergic neurons, does not only promote neuronal survival and 
axonal  branching  but  also  enhances  the  functionality  of  these  neurons.  Cass  et  al.  (1999)  
reported that already after 24 h after intrastriatal administration of GDNF, there was an 
increase in methamphetamine-stimulated DA release both in the striatum and SN. Even 
though the basal release and tissue concentration of DA were not augmented by GDNF, 
increased concentrations of its metabolites indicate an increase in DA turnover. Therefore, if 
the mechanisms behind the positive behavioural response to VEGF-C were to be explored 
further, measurements of eg. TH activity or DA release might clarify our findings.  
We found that  the  MAPK/ERK –pathway  was  activated  by  VEGF-C in  the  rat  striatum.  This  
intracellular signalling pathway is also activated by numerous other neurotrophic factors. ERK 
phosphorylation was clear at 1 h after VEGF-C injection, but at 8 h post-injection the variation 
between samples had increased and the level of activation was not statistically significantly 
different from control levels. It is known that ERK activity can lead to distinct responses even 
in the same cell type depending on e.g. duration and magnitude of phosphorylation (Ebisuya 
et al., 2005). We postulate that if VEGF-C induces only a transient activation of ERK, 8 h post-
injection may represent a kind of threshold time point, when the activation starts to 
disappear, and therefore can be seen only in some samples. 
 
6.3 Neither VEGF-C nor GDNF are neurorestorative in a severe unilateral 
6-OHDA rat model (II) 
Since we observed a decrease in D-amphetamine –induced rotational behaviour in 6-OHDA –
lesioned rats that were injected intrastriatally with VEGF-C before lesioning, we decided to 
assess if it has any neurorestorative activity after 6-OHDA -administration. When 6-OHDA 
and VEGF-C or GDNF were given as one deposit  with one-month interval,  there was a trend 
towards reduced rotational behaviour during the 10 weeks of follow-up in both experiments in 
NTF-treated groups. However, the effects were not significantly different from the vehicle 
group. In our hands, a one-site 6-OHDA –lesion seems to produce highly variable rotational 
behaviour  and  may  be  considered  even  unstable,  since  many  rats  show  spontaneous  
functional recovery. This phenomenon may interfere with the evaluation of neuroprotective or 
neurorestorative efficacy of new NTFs. Therefore another model, created with two deposits of 
6-OHDA,  was  employed.  This  approach,  however,  produced  such  a  severe  lesion  that  even  
GDNF was without significant effects. In this context, since GDNF is one of the most potent 
NTFs for DAergic cells known to date, it is not surprising that we could not detect any effect of 
VEGF-C in our neurorestoration experiments.  
 
Striatal reinnervetion has been observed after a single GDNF –injection (Aoi et al., 2000a, 
Lindholm et al., 2007, Voutilainen et al., 2009) and after sequential GDNF –administration 





striatal 6-OHDA lesion. On the other hand, Rosenblad et al. (2000) did not find any consistent 
striatal improvements in rats with extensive striatal lesions when the animals received a long-
term GDNF –treatment first in the SN followed by sequential administration into the striatum. 
However,  an  increased  survival  of  TH-positive  cells  in  the  SN  and  axonal  sprouting  in  the  
globus pallidus were seen, proving that GDNF had a positive effect on the DAergic cells. We 
postulate that the lack of efficacy of GDNF in the more extensive lesions, such as ours, may be 
due to insufficient retrograde transport of GDNF as the axonal terminals are almost abolished, 
and therefore also the axonal sprouting is minimal. This would interrupt the retrograde 
transport of GDNF, which has been suggested to be important for the survival-promoting 
effects of GDNF (Tomac et al., 1995). However, there are reports describing also anterograde 
transport, evidently via GABAergic neurons, when GDNF is expressed in the striatum using 
viral vectors (Kordower et al., 2000, Georgievska et al., 2004). If GDNF is then released in the 
SN after anterograde transport,  it  may contribute to the survival  of  DAergic cells,  and play a 
role also in our findings of increased TH-cell survival while a robust striatal and behavioural 
recovery  was  lacking.  It  is  also  possible,  that  VEGF-C  does  not  possess  any  neurorestorative  
activity, but its positive effects are restricted to neuroprotection. 
 
6.4 VEGF-C induces gliosis and disrupts the BBB (II) 
We detected a prominent activation of microglia and expression of GFAP-positive astroglia, as 
well as a reduction in immunoreactivity of intact blood vessels (endothelial barrier antigen 
staining) three days after VEGF-C was injected into intact rat  brain.  These results  are similar 
to those reported for VEGF-A. Although VEGF-A clearly has supportive effects on various 
neurons, and outcomes in preclinical animal models of neurodegenerative disorders have been 
positive, the safety of a vascular growth factor may be an issue when considering its 
therapeutic use. VEGF-A-induced neovascularisation may be a desired and positive effect in 
certain disorders, but detrimental when uncontrolled and accompanied by vascular leakage 
that may follow after higher doses. VEGF-B, however, seems to be devoid of vascular and glia-
inducing effects in the brain, which is likely due to its high receptor selectivity (Poesen et al., 
2008). 
These signs on one hand suggest that VEGF-C may not be safe as a therapeutic molecule, but 
on  the  other  hand  remind  that  little  is  known  about  the  borderline  between  beneficial  and  
harmful astro- and microgliosis.  As reviewed by Hanisch and Kettenmann (2007), activation 
of microglia can produce protective effects in some neuropathological states. Even though 
current evidence proposes that microglial activation is detrimental in models of PD, this may 
be partly due to experimental conditions  that often provoke robust defence mechanisms and 
lead to a highly reactive microglial state (for example when using lipopolysaccharide). 
Astroglial cells, however, are known to secrete survival-promoting agents such as NTFs. Since 
we studied the occurrence of glial activation only at one time point, chosen to reveal the effect 
at maximum, it is not known how long the phenomenon exists after VEGF-C administration. 
This could be crucial information, since sustained reactive microgliosis may be the more 
harmful phenomenon rather than astrogliosis. VEGF-A, for example, causes a transient 





and reaching control values in a week (Rite et al., 2007). In the same study, astrogliosis peaked 
at day 4 post-injection and but was still evident at 3 weeks post-injection. 
 
6.5 Nigral DAergic neurons of MEN2B knock-in mice are protected from 
6-OHDA –toxicity (III) 
MEN2B knock-in mice carry the Met918Thr –missense mutation in the RET receptor tyrosine 
kinase. The mutation renders the receptor constitutively active, and causes a cancer syndrome 
(multiple  endocrine  neoplasiatype  2).  RET  is  also  one  of  the  main  signaling  receptors  for  
GDNF, and it is expressed by nigrostriatal DAergic neurons (Nosrat et al., 1997, Trupp et al., 
1997). Mijatovic et al. (2007) have studied changes in the brain DAergic system of these mice 
and have observed robustly elevated concentrations of DA and its metabolites in the striatum, 
cortex and hypothalamus, increased levels of TH (striatum and SN) and DAT (striatum), and 
even slightly increased numbers of TH-positive cells in the SNpc and DAT-positive varicosities 
in the striatum. The peculiarities in the DAergic transmission of these mice were further 
confirmed by findings of augmented DA synthesis, storage, and stimulated release (Mijatovic 
et al., 2008). The next step after these findings was to study the effects of known DAergic 
neurotoxins, 6-OHDA and MPTP, in these mice and to assess how constitutive RET signalling 
affects the neurodegenerative process induced by the toxins. The elevated levels of DA and 
increased expression of DAT in MEN2B M/M- mice could sensitize them to the effects of the 
toxins, since excess DA is harmful to neurons, and both 6-OHDA and the toxic metabolite of 
MPTP (MPP+) enter the neurons via DAT (Blum et al., 2001, Chen et al., 2008).  
We induced rotational behaviour in 6-OHDA –lesioned MEN2B mice to monitor the success 
of lesioning procedure. The result from the rotational experiment cannot reliably be used to 
assess the extent of the lesion in these mice because of the special features in their DAergic 
transmission. In comparison to WT littermates, M/M mice rotated more despite a lower 
percentual drop in striatal DA content. The behavioural effect is most likely due to higher 
release of DA in the intact hemisphere in M/M mice. Additionally, we found a notable 
difference in the survival of nigral TH-positive cells between the genotypes. While in the WT 
mice approximately 36 % of cells had degenerated (or lost their TH-phenotype) at 3 weeks 
post lesion, hardly any changes could be observed in M/M mice. The nigral DAergic cells were 
almost completely preserved despite a substantial loss of striatal DA, which interestingly was 
not compensated by elevated DA turnover in M/M mice in contrast to WT mice. Therefore, 
we suggested that constitutive RET activity is an important mediator of neuroprotection by 
GDNF in the DAergic cell bodies, whereas other mechanisms independent of RET are needed 
to preserve the axons. It must be noted though, that we studied rather acute 
neurodegeneration during the course of 3 weeks and therefore cannot completely rule out the 
possibility that constitutive RET activity might lead to enhanced axonal regeneration with 
time.  
In the same publication, we report results from an experiment in which MEN2B mice, their 





consecutive days. This intoxication regime resulted in striatal depletion of DA, which was 
approximately 50 % in all genotypes. Striatal TH-immunoreactivity was likewise reduced by 
about 25 % in all groups, but the DAergic cells in the SN were left intact. We speculated that 
our choice of MPTP –intoxication, milder than usual, may have been inefficient in inducing 
proper neurodegeneration. It has been also shown that mice can exhibit spontaneous recovery 
from MPTP –treatment, manifested as a gradual increase in striatal TH-immunoreactivity and 
recovery of striatal DA, albeit that these effects may stay incomplete (Mitsumoto et al., 1998). 
Therefore, it is difficult to make conclusions about the MPTP –experiment in MEN2B mice.  
 
6.6 D-Amphetamine-induced locomotor activity is attenuated in 
mPrPh(A30P)asyn +/+ mice (IV) 
mPrPh(A30P)asyn transgenic +/+ -mice express the mutated human  A30P-aSyn under the 
control of the pan-neuronal mouse prion protein promoter. The mice have been studied to 
some extent earlier (Yavich et al., 2004, Yavich et al., 2005, Oksman et al., 2009). According to 
these reports, +/+ -mice exhibit several motor impairments, including reduced locomotion 
and rearing, weaker performance on the rotarod, as well as attenuated locomotor response to 
L-DOPA. They also have a higher brain aSyn load as assessed by western blotting,  which we 
confirmed by immunohistochemistry. Nevertheless, DAergic neuropathology, such as loss of 
neurons or striatal DA, has not been observed. Instead, the readily releasable pool of DA is 
exhausted faster by intensive electric stimulation in these mice (Yavich et al., 2004, Yavich et 
al., 2005). This finding implies that there is a lower capacity or inadequate recruitment of DA 
storage pool, which supposedly offers replenishment to the readily releasable DA pool under 
heavy stimulation. 
D-amphetamine-induced locomotor activity was measured in 6-month-old mPrPh(A30P)asyn 
mice, since there were no detectable differences in their basal 24-h activity. Also, we intended 
to use D-amphetamine later in the experiments to induce rotational behaviour in 6-OHDA-
lesioned mice, and decided to evaluate whether those results could possibly be influenced by 
basal  differences  in  response  to  the  drug.  We  observed  that  +/+  mice  have  a  significantly  
reduced response to 1 mg/kg of D-amphetamine when compared to their wild type littermates. 
Amphetamines can affect the release of DA through various mechanisms, one of the main 
routes being the inhibition and reversal of DAT function to increase extracellular DA 
concentrations (Sulzer et al., 2005). However, since mPrPh(A30P)asyn +/+ mice have normal 
levels of DAT in the striatum and there are no significant changes in the rate of DA reuptake 
(Yavich et al., 2005), defects related to DAT can most likely be ruled out as an underlying 
cause for our observation. We suggest that the described deficits in DA dynamics play a part 
in our observation of decreased locomotor response to a small dose of D-amphetamine. 
Interestingly, when the dose was increased to 2.5 mg/kg, the distance travelled did not differ 
significantly between the genotypes. We cannot rule out that the earlier low dose of the drug 
did  not  play  any  role  in  how  the  mice  responded  to  the  higher  dose.  Vanderschuren  et  al.  
(1999) have reported that a single injection of amphetamine (5 mg/kg) could sensitize rats to 
the stimulating effects of the second injection, which followed 3, 7 or 21 days later. The 





but still points out the problem of interpreting behavioural responses after repeated injections 
of  a  psychostimulant  drug.  It  is  also  possible  that  2.5  mg/kg  was  simply  too  high  a  dose  to  
detect similar differences as with 1 mg/kg in locomotor activity in our mice. 
 
6.7 The effects of 6-OHDA in mPrPh(A30P)asyn mice (IV) 
Considering  the  complex  etiology  of  PD,  it  has  been  hypothesized  that  more  than  one  
“triggering factor” may be needed to start the neuropathological process. There is an 
increasing amount of evidence of susceptibility genes that do not alone explain the 
appearance of PD (Wirdefeldt et al., 2011). For example, polymorphisms in the SNCA gene 
encoding  for  aSyn  are  related  to  sporadic  PD  in  addition  to  the  point  mutations  and  
multiplications of the gene that are linked to familial PD (Bekris et al., 2010). In this context, 
and since the mPrPh(A30P)asyn mice have a rather mild motor phenotype and are without 
PD-like neuropathology, we decided to challenge the mice with 6-OHDA to see if the 
expression of human mutated aSyn would predispose them to the effects of the toxin.  
Stride lengths were not significantly affected by 6-OHDA in either genotype, but it was 
generally shorter in 6-OHDA –treated mPrPh(A30P)asyn +/+ mice. However, the reduction in 
stride length does not necessarily correlate with the magnitude of nigral cell loss, which may 
explain the lack of 6-OHDA dose effect (Iancu et al., 2005). More robust changes were seen in 
D-amphetamine –induced rotational behaviour, and the general conclusion from these 
experiments is that the WT/WT mice required a higher dose of 6-OHDA than +/+ mice to 
exhibit a robust ipsilateral rotational bias. This, however, was not a sign of increased 
sensitivity to 6-OHDA, since striatal DA was similarly depleted in both genotypes at higher 
doses of 6-OHDA, and there were no genotype effects in the reductions of DAergic 
immunohistochemical markers. At the lowest dose of 6-OHDA (0.33 µg), the +/+ mice 
paradoxically rotated mainly contralaterally, and also had an elevated amount of DA in the 
toxin-treated striatum. We suggest that the differences between the genotypes in rotational 
behaviour  are  due  to  the  functional  deficits  in  DA release  (Yavich  et  al.,  2004,  Yavich  et  al.,  
2005). These defects may have been enhanced with 6-OHDA -treatment in +/+ mice. What 
comes to the puzzling effect of the lowest dose of 6-OHDA, it may well be that the dose was 
so low, that it corresponds to a mere mechanical lesion caused by the injection needle. Such a 
mechanical damage in the mouse striatum can result in increased TH-activity, increased DA, 
DOPAC and HVA, as well as proliferation of presynaptic DA uptake sites (Howells et al., 1996). 
There was no difference in striatal DAT –immunoreactivity between the mPrPh(A30P)asyn 
genotypes, but DA and its metabolites were clearly increased in +/+ mice. However, our 
experiments do not offer an explanation to why this phenomenon does not happen in both 
genotypes.  
In contrast to the earlier report (Yavich et al. 2005), basal DA and DOPAC –levels were slightly 
elevated in the mPrPh(A30P)asyn +/+ mice in our studies.  Also, DOPAC/DA –ratio was 
significantly raised in the intact and 0.33 µg of 6-OHDA –treated striata in +/+ mice. This rise 





compensatory  mechanism  to  make  up  for  reduced  DAergic  transmission  eg.  in  6-OHDA  –
lesions (Melamed et al., 1980). Therefore, we speculate that the defects in DA release in 
mPrPh(A30P)asyn +/+ lead to increased DA and DOPAC tissue concentrations and are 
reflected in presynaptic DA turnover, since the HVA/DA –ratio was clearly elevated only by 
the highest dose of 6-OHDA and not affected by genotype.  
Also striatal 5-HT concentrations in mPrPh(A30P)asyn +/+ mice were higher than in WT/WT 
mice. Since 5-HT has complex modulatory effects on striatal DAergic function and output, this 
finding might require some further investigations. It has been reported that WT aSyn can 
attenuate the cell-surface availability of the serotonin transporter (Wersinger et al., 2006). 
Although the interaction does not seem to be mediated by the lipid binding domain of aSyn 
(residues 1-57, affected by the A30P -mutation), it might be of interest to study the trafficking 
and  function  of  serotonin  transporter  in  mPrPh(A30P)asyn  mice,  since  they  also  express  the  
WT aSyn.  
 
6.8 Relevance of the current studies to clinical research 
As mentioned before, there are several NTFs that have been effective in preclinical models of 
PD,  but  only  two  have  made  it  to  clinical  trials  with  controversial  outcomes.  One  of  the  
suggested reasons for why GDNF-trials failed, is the poor diffusion of the protein in the brain 
parenchyma.  Studies  in  rhesus  monkeys  have  shown  that  the  diffusion  pattern  of  infused  
GDNF is very unpredictable and can vary over four-fold between individuals (Salvatore et al., 
2006).  In  another  study,  there  was  a  positive  correlation  between  the  volume  of  GDNF  
distribution, motor improvement and preservation of striatal TH-innervation in MPTP-
intoxicated monkeys (Gash et al., 2005). These findings may be of pivotal importance when 
planning new clinical trials with NTFs. Our studies demonstrated that one possible approach 
to  improve  the  diffusion  properties  of  a  protein  is  structural  modification,  in  this  case  the  
removal of heparin-binding domain of GDNF. Although this compromised the neurotrophic 
potency of the protein, the molecule was not completely ineffective in vivo.  It  would  be  
interesting to know if the efficacy of the truncated protein could be improved by longer term 
administration. Still, it should be kept in mind that improving the diffusion may bring about 
other  challenges,  for  example  how  to  control  the  diffusion.  If  it  is  only  a  certain  neuronal  
population that needs to be targeted, how can it be ensured that no severe adverse effects are 
caused by uncontrolled diffusion to other brain areas? Also, the safety of long-term delivery of 
NTFs  needs  to  be  carefully  assessed,  since  NTFs  are  involved  in  neuronal  cell  growth,  
migration, differentiation and survival, which could possibly promote the appearance of 
malignancies. MEN2B syndrome, for example, is characterized by a high frequency of 
medullary thyroid carcinomas and pheocromocytomas (Moline and Eng, 2011). The syndrome 
is caused by mutations in the gene coding for RET, rendering it constitutively active and 
perhaps leading to loss of substrate specificity. As mentioned, RET is one of the main 
signalling receptors for GDNF. Although brain malignancies are not commonly found in 
MEN2B –patients, the syndrome is still a warning example of what may follow of sustained 





It is also intriguing that many growth factors serving their main functions outside the nervous 
system can have neurotrophic properties in mature neurons. These findings offer us new 
insights into the complex regulation and maintenance of neurons under both physiological 
and pathological states. It is possible that additional benefit can be achieved by combining 
NTFs, perhaps even specifically for different neurodegenerative disorders. For example, we 
found in our studies that nigral TH-positive cells were slightly more efficiently protected in 
the 6-OHDA-lesioned rats by combining VEGF-C and GDNF, than with either of the proteins 
alone. The benefit of combination therapy could be mediated by either activation of separate 
survival-promoting intracellular signalling pathways by the trophic factors, or simply through 
actions on different cells. However, great caution is required when considering growth factors 
that primarily affect other tissues for treating brain disorders. VEGFs undoubtedly have 
positive effects on neurons and could be potential targets in drug development, but they may 
have  severe  adverse  effects  such  as  vascular  leakage  that  can  lead  to  brain  oedema.  We also  
demonstrated that VEGF-C activates microglia, which may cause neuroinflammation, and it 
may also open the BBB. Additionally, although it was reported only once by Xue et al. (2010) 
that striatal expression of EPO in the rat brain via AAV-vector leads to systemic effects in rats 
(ie. increase in red blood cells), the chance for unexpected systemic adverse effects should be 
kept in mind. 
Emergence of genes associated with PD, as well as identification of NTFs for DAergic neurons 
have allowed the development of genetically modified mouse strains. Although these mouse 
strains rarely and inconsistently exhibit both behavioural and neuropathological hallmarks of 
PD, their usefulness may rather lie in clarifying the mechanisms of neurodegeneration. The 
growing list of PD-related genes, as well as all the putative causes of sporadic PD suggest that 
what we clinically know as PD is the manifestation of various underlying factors. It is possible, 
that the sequences of events that finally lead to neurodegeneration differ depending on the 
background of the patient. Therefore, better understanding of how neurons degenerate may 









The aims of the present studies were to analyse the effects of novel or modified known NTFs 
and to investigate the effects of selected genetic backgrounds on induced DAergic 




1. The  removal  of  the  first  38  amino  acids  from  the  structure  of  GDNF  results  in  
increased diffusion of the protein in the rat striatum, but its effects on functional 
recovery and preservation of the nigrostriatal DAergic pathway are attenuated in the 
6-OHDA –lesioned rats when compared to the full-sequence GDNF. 
 
2. VEGF-C has neuroprotective effects in the 6-OHDA –treated rats, but its 
neurorestorative activity remained unconfirmed. VEGF-C effectively abolishes the 
rotational bias although its effect on the survival of DAergic neurons was rather 
modest.  It  was  also  seen  that  VEGF-C  can  induce  astro-  and  microgliosis  and  
disruption of the BBB when injected intrastriatally. 
 
3. Constitutive RET signalling provides a robust protection of nigral DAergic neurons in 
MEN2B M/M mice against 6-OHDA in spite of substantial depletion of striatal DA. 
This suggests that other mechanisms than RET –signalling are involved in axonal 
protection by GDNF. 
 
4. Transgenic mice expressing the human A30P-aSyn are not sensitized to the neurotoxic 
effects  of  6-OHDA  although  they  exhibit  a  particular  rotational  bias  and  changes  in  
striatal DA after the toxin treatment. These mice have an attenuated locomotor 
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